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RNA interference (RNAi) is a conservative post-transcriptional gene silencing 
mechanism that can be mediated by small interfering RNAs (siRNAs). Given the 
effectiveness and specificity of RNAi, the administration of siRNA molecules is a 
promising approach to cure diseases caused by abnormal gene expression. However, as 
siRNA is susceptible to degradation by nucleases and it can hardly penetrate cell 
membranes due to its polyanionic nature, a successful translation of the RNAi mechanism 
for therapeutic purposes is contingent on the development of safe and efficient delivery 
systems. This dissertation described the development of novel siRNA delivery systems on 
the basis of polymeric and dendrimeric materials and also demonstrated the application of 
one optimized delivery system to deliver therapeutic siRNAs in a cardiovascular disease 
model in vivo. We studied a linear peptide polymer made from cell penetrating peptide 
monomers and investigated the contribution of the polymeric structure, degradability, and 
ligand conjugation to the siRNA loading capacity, biocompatibility, and transfection 
efficiency of polymeric materials. With the obtained knowledge and experience, we 
invented a neutral crosslinked delivery system aiming to solve the inherent drawbacks of 
traditional cationic delivery systems that are based on electrostatic interactions. The new 
concept utilized buffering amines to temporarily bind siRNA and a crosslinking reaction to 
immobilize the formed particles, and targeting ligands modified on the neutral dendrimer 




The obtained delivery system allowed stability, safety, controllability, and targeting ability 
for siRNA delivery, and the method developed here could be transformed to other 
polymeric or dendrimeric cationic materials to make them safer and more efficient. To 
exploit the therapeutic potential of siRNA delivery, we developed a tadpole-shaped 
dendrimeric material to deliver siRNA against an Angiotensin II receptor in a rat 
ischemia-reperfusion model. Our results showed that the nonaarginine-conjugated tadpole 
dendrimer was capable of delivering siRNA effectively to cardiac cells both in vitro and in 
vivo, and the successful down-regulation of the Angiotensin II receptor preserved the 
cardiac functions and reduced the infarct size post-myocardial infarction. This dissertation 
paves a way for transforming multifunctional non-viral siRNA delivery systems into 




CHAPTER 1  
INTRODUCTION 
 
Gene therapy is becoming increasingly attracting to improve human health. The 
discoveries revealed by the human genome project demonstrated the underlying genetic 
causes for inherited diseases [1], and it is estimated that more than 10,000 human diseases 
relate with genetic abnormalities. With the rapid development of academic researches and 
modern techniques, numerous gene targets that are deregulated or dysfunctional under 
particular circumstances have been identified for critical diseases. Therefore, increasing 
the expression of protective genes or decreasing the expression of pathogenic genes or 
harmful genes could be a potent strategy for disease management.  
1.1 Motivation 
The discovery of RNA interference (RNAi) mechanism widens the door for gene 
therapy [2-6]. The high specificity and high efficiency of RNAi make the fine regulation of 
a target gene become possible. To utilize the endogenous post-transcriptional gene 
silencing mechanism, appropriate trigger molecules need to be introduced into target cells 
to initiate the RNAi process, and the most efficient triggers are small interfering RNA 
(siRNA) and microRNA. Compared to microRNAs and other types of molecules that are 
capable of suppressing RNA translations, such as ribozymes, DNAzymes, antisense 
oligonucleotides (ASO), and decoys, siRNA molecules own unique strengths [7]. They 
have completely matched double-stranded structures, which makes them relatively stable 
compared to single-stranded RNAs. It is easy to design and synthesize the siRNA sequence 




the design of complicated structures as seen in ribozymes and DNAzymes. The 
development of siRNA therapeutics is paving a way for realizing the personalized therapy 
and meeting the unmet clinical needs [8].  
However, the knowledge of gene abnormalities upon illnesses is far behind from 
being fully translated for therapeutic purposes due to the lack of safe and efficient delivery 
systems. Currently, clinical trials of gene therapy are dominated by viral vectors, 
unfortunately with the risks of mutagenesis, immunogenicity, and virus leakage [9], while 
chemically synthesized carriers are more controllable but less efficient. Most clinical trials 
using siRNA molecules as the drug molecules aim for local treatments, such as the ocular 
system, which is relatively less challenging; however, problems with the systemic delivery 
and the delivery to other organs that are deep in the human body still remain unsolved. 
Such situation greatly restricts the application of RNAi therapeutics. This dissertation 
focuses on the development of novel delivery systems based on polymers and dendrimers 
first in vitro and then translating such delivery systems in a cardiovascular disease model in 
vivo.  
1.2 Research Objectives 
A competent siRNA delivery system should be able to overcome at least 2 
biological barriers, the negatively charged cell membrane and the intracellular endosomal 
membrane. As to the systemic delivery systems, penetrating the endothelial layer is 
another hurdle to conquer. Except these basic requirements, the siRNA loading efficiency, 
vehicle stability, toxicity, and degradability are also worth considering. To produce a 
qualified delivery system, the key factors that finally affect the delivery efficiency need to 




applicable design. With this purpose, polymers and dendrimers were studied in this 
dissertation.   
Polymeric materials are highly diverse regarding the structures, sizes, and functions, 
allowing a great space for the design toward a particular aim. At present, polymers have 
been widely used as delivery vehicles [10, 11]. Some are composed of unified monomers, 
while some are hybrids of various components that can realize different actions. The 
properties and performance of a polymeric material associate with many factors, and 
sometimes even a slight variation may lead to a significant distinction. To understand the 
underlying mechanism, in the first part of the dissertation a synthesized linear polymer 
composed of oligo-peptide monomers was studied to understand how the size and the 
degradability affect the characteristics of the polymer as well as the final transfection 
efficiency in vitro, and whether the introduction of an integrin-binding ligand could 
improve the efficacy was also studied. 
Dendrimers are popular and promising in constructing drug delivery systems [12, 
13]. They have defined chemical structures with tunable numbers of branches, peripherals, 
and generations, so they can be designed to deliver a certain category of cargoes with 
controllable loading efficiency and affinity. As to siRNA delivery, dendrimers hold an 
additional advantage of the endosomal escape ability to release siRNA into cytoplasm 
where the RNAi takes place. The nature of dendrimers is suitable for siRNA delivery; 
however, their toxicities bring safety concerns when it comes to the translation for 
therapeutic purposes. In the second part of the dissertation, the surface characteristic of the 
original cationic dendrimer was redesigned, and a crosslinking strategy was invented for 




Myocardial infarction (MI) is a life-threatening cardiovascular disease that was 
usually caused by the occlusion of coronary arteries due to floating atherosclerotic plaques. 
Even if patients can survive from the initial attack, the following loss of heart muscle 
contractility and progressive ventricle dysfunction can hardly be prevented. Currently, the 
only definite cure is the heart transplantation, but the availability of heart donors and the 
risk of consistent activations of the immune system may present as potential issues, thus 
the treatment of cardiovascular diseases demands a significant breakthrough. Till now gene 
therapy rarely expands to cardiac tissue because of the lack of suitable delivery vehicles. In 
the third part of the dissertation, with the knowledge and experience obtained in the first 
two parts, a hybrid material of dendrimers and polymers was developed into a siRNA 
delivery system and was exploited in a cardiovascular disease model.   
1.3 Specific Aims 
The central hypothesis of this dissertation is that the design of multifunctional 
polymeric materials will lead to a safe and efficient siRNA delivery system with potential 
cardiovascular applications. The central hypothesis was studied following three specific 
aims. 
Specific Aim 1: Investigate the key factors of polymeric materials based on 
degradable cationic polymers 
We hypothesized that a degradable backbone could alleviate the toxicity from 
high-density charges and meanwhile preserve the strengths of the polymeric structure. We 
used an oxidative condensation method to synthesize polymeric oligo-arginine peptides 
linked with reducible disulfide bonds, and the performances of the obtained materials were 




using the short oligo-arginine and a non-reducible arginine polymer in comparison. To 
investigate the contribution of functional ligands, a RGD peptide was further modified on 
the reducible arginine polymer, and the transfection efficiency of the un-modified and 
modified materials were compared. 
Specific Aim 2: Develop a neutral crosslinked dendrimeric system to overcome the 
drawbacks of traditional cationic systems  
We hypothesized that the neutral peripherals of a dendrimer is the key to reduce 
toxicity, and its buffering amines at the joint points could be utilized to carry siRNA at low 
pH. We developed a novel category of neutral dendrimers by replacing their surface 
cationic groups with physiologically non-charged hydrazides and targeting saccharide 
molecules, and we established a method to construct the neutral crosslinked delivery 
vehicles based on a crosslinking reaction. The siRNA loading efficiency, particle size, 
stability, controlled release of siRNA, and targeting capability were studied with varied 
crosslinker concentrations and saccharide densities on the dendrimer surface. 
Specific Aim 3: Exploit the therapeutic potential of an optimized siRNA delivery 
system in a cardiac ischemia-reperfusion model  
We hypothesized that the suppression of AT1R by RNAi would prevent Ang II 
activation and preserve cardiac functions after MI injury. We developed several 
tadpole-shaped dendrimeric materials for siRNA delivery with different CPP modifications 
and screened out a potent material that showed the strongest performance in vitro. The 
selected tadpole dendrimer was used to delivery siRNA against AT1R intramyocardially in 
a rat ischemia-reperfusion model. Gene expression levels of AT1R and relative genes in 




and compared after the treatment. 
Successful completion of the dissertation would lead to novel non-viral siRNA 
delivery systems for gene therapy, such as for cardiovascular diseases. 
1.4 Background 
1.4.1 RNAi mechanism and RNAi therapeutics 
RNAi mechanism 
Since Andrew Fire and Craig Mello revealed the mechanism of RNAi, it has been 
extensively employed in basic investigations of gene functions and regulations of gene 
expression levels with engineering or therapeutic purposes. Two main pathways have been 
identified in the RNAi mechanism, the siRNA pathway and microRNA pathway.  
siRNA molecules have completely complementary duplex structures, normally 
19-23 nt in the length with 2 nt overhangs at 3’ terminals. siRNA can be produced from 
long double-stranded RNAs (dsRNAs) by a endoribonuclease Dicer or be introduced 
exogenously into cytoplasm, and then a protein complex named as RNA Induced Silencing 
Complex (RISC) incorporates siRNA and activates it by discarding its sense strand. The 
remaining anti-sense strand guides the RISC to recognize the homologous mRNA, and a 
local double-stranded structure forms after the base-paring. An endonuclease in RISC 
cleaves the double-strand part, leading to the degradation of the specific mRNA. Moreover, 
the existence of RNA dependent RNA Polymerase (RdRP) further amplifies the amount of 
small RNA molecules after RNAi initiation. RdRP extends the double-stranded structure of 
mRNA using the anti-sense strand of siRNA as the primer and the mRNA as the template, 




structures as siRNAs, which can trigger more RNAi processes. As a result, the RdRP 
mechanism makes the gene silencing effect even more efficient and sustaining.  
The other important pathway is driven by microRNA. microRNA pathway shares 
the similar mechanism and cellular machineries of siRNA pathway with 3 major 
differences. First, a mature microRNA is produced from pre-microRNA endogenously via 
post-transcriptional modifications with P-bodies involved, so the origin of microRNA 
molecules and initial process of microRNA pathway are different from the siRNA pathway. 
Second, microRNAs have mismatched parts in their duplexes, presenting like a loop in the 
center, not completely complementary in the sequences, which leads to the third difference 
regarding the silencing mechanism. In microRNA pathway, if the leading strand of 
microRNA is completely complementary to the mRNA, the mRNA will be cleaved and 
degraded as the siRNA pathway, otherwise the mRNA will be prevented from being 
translated. In both pathways, the small RNA molecules are the triggers for gene silencing, 
so the delivery of siRNAs or microRNA mimics to target organs holds promises in treating 
diseases caused by gene expression disorders.  
RNAi therapeutics 
Compared to traditional drugs, small RNA molecules, which initiate RNAi in the 
cytoplasm, have great potentials due to the sequence specificity and ease of design and 
synthesis. In addition, the RNAi mechanism regulates the targets at the gene expression 
level instead of simply blocking a receptor or a pathway, which may avoid the risk of 
causing deficiency or dysfunction in endogenous feedback loops.  
Despite all the advantages of RNAi therapeutics, its clinical use has not been fully 




vulnerable to degradation by RNases. Since Elbashir et al. demonstrated the usage of 
siRNA duplexes [7], the research focusing on how to deliver siRNA efficiently and 
controllably has never stopped, but few met the high standard for gene drugs in safety and 
efficacy. To date, more than 30 clinical trials involving 21 different siRNA or shRNA drugs 
are in process, targeting 14 diseases, such as HIV/AIDS, cancer/tumor, kidney injury, 
age-related macular edema (AMD), diabetic macular edema (DME), non-arteritic ischemic 
optic neuropathy (NAION), familial adenomatous polyposis, etc. Most therapeutic RNA 
molecules were applied naked or via viral vectors, while 8 trials are using synthetic carriers 
to deliver RNA molecules via intravenous administrations [14]. Among them six are 
dependent on liposomes or lipid vehicles [15-17], one is based on cyclodextrin 
nanoparticles [18], and one employs a degradable polymeric matrix. Though the clinical 
studies are showing positive results, the development of RNAi therapeutics still stays in an 
early stage, and the published gene silencing effects, around 20% reduction in gene 
expression, were not as high as detected in vitro [15]. Therefore, new delivery systems for 
RNAi therapeutics need to be developed to achieve better efficiency and broader 
applications in vivo.  
 siRNA and microRNA share similar structures as well as similar deficiencies in 
the delivery process, such as difficulties in overcoming biological barriers and having a 
short half-life. As the design for siRNA sequence is easy and the target gene is clear and 
selectable, the development of delivery systems for siRNA set off earlier than that of 
microRNA. However, with the recent revealing discoveries of functional microRNAs, 
particularly the ones relating to stem cell differentiation and myocardial regeneration, the 




it’s likely to expand the use of siRNA delivery systems to microRNA, and vice versa. 
1.4.2 Synthetic carriers in siRNA delivery 
Polymers in siRNA delivery 
Polymeric materials, particularly cationic polymers, have been regarded as 
valuable players in siRNA delivery. Compared to large and flexible DNA plasmids, siRNA 
molecules are smaller, more rigid, and more sensitive in sequence regarding their affinity 
to cationic materials [22]. All of these make siRNA harder to be condensed into stable 
particles and hence require stronger interactions to achieve that goal. Upon such 
requirments, ploymers serve as competent candidates. By changing the structure and the 
number of repeating units, the molecular weight and characteristics of polymers can be 
finely adjusted. Large molecule materials are suitable to complex siRNA molecules into 
nano- or micro-particles through electrostatic interactions and neutralize the anionic 
charges of the phosphate backbone, enhancing the translocation of siRNA across cell 
membranes. By forming particles with cationic polymers, siRNA not only becomes more 
resistant to nuclease digestion but also gains a longer half-life in circulation, especially 
when some stabilizing polymers are introduced into the vehicles, such as poly(ethylene 
glycol) (PEG). Meanwhile, polymers also may serve as the scaffold to allow the decoration 
of other segments with additional functions so as to become ―intelligent‖, like ligands for 
endosomal escape, ligands recognizing specific receptors or cells, pH sensitive elements, 
etc. Therefore, siRNA delivery systems derived from polymers are being exploited by an 
increasing number of research groups.  




polymeric materials have rarely been studied in details. For instance, how the length or size 
of the polymers affects their performance, how the degradability determines polymers’ 
properties, and how much improvement could be obtained with the modification of 
functional ligands. Being able to answer these questions will get us further understanding 
and better perspectives of polymeric delivery systems.  
Besides, the toxicity issue of cationic polymers is another big concern. The cations, 
most likely primary amines, which are the main source of positive charges in polymers, 
have been found to cause membrane damage, apoptosis pathway activation, and medium 
depletion [23-26], finally leading to cell death. The toxicity of polymers associates with 
their molecular weights, as polymers like poly-L-lysine (PLL) [27], poly-L-arginine (PLR) 
[28], and polyethyleneimine (PEI) [29, 30] induced more severe damages when their 
molecular weights were high, likely due to the increased number and density of positive 
charges, whereas decreasing the size of polymers would compromise the efficiency. To 
find the right balance for cationic polymers between transfection efficiency and safety 
exhibits as a great challenge even today. 
Dendrimers in siRNA delivery 
Dendrimers constitute a category of radially-symmetric, highly branched 
macromolecules, with well-defined and mono-disperse structures. Typical dendrimers are 
composed of three components: the core, the interior branches, and peripheral groups 
(Figure 1.1). With a sophisticated design and the control of chemical synthesis, dendrimers 
of a certain generation can be obtained with a tunable number of peripheral groups. Most 
dendrimers used in gene delivery prefer primary amines as peripheries, like polyamido 




charged amines are capable of complexing siRNA directly with strong affinities, leading to 
the formation of tight polyelectrolyte particles. Also attributed to the chemical activities of 
amine groups, various functional ligands, including peptides, saccharides, aptamers, and 
drug molecules, can be selectively modified on the surface of dendrimers with controllable 
densities and topologies [13, 31-33]. 
 
 
The unique multivalent effect gained from high-density ligands on dendrimers can 
further amplify the interaction between ligands and their receptors or substrates, and the 
activities of multivalent ligands exhibit significant enhancements that cannot be gained 
only by the sum of individual bindings [34, 35]. An increasing number of studies are 
utilizing the multivalency to achieve enhanced cell binding, highly selective cell 
recognition, or increased internalization rate of glycodendrimers or peptide dendrimers 
[36-40]. 
Figure 1.1 Scheme of a typical dendrimer. (a) Component and structure of a 
dendrimeric material; (b) bioactive dendrimers can interact with specific receptors 






A charitable nature of amine-derived dendrimers is the buffering capacity attributed 
to the secondary and tertiary amines inside the structures. These amines tend to capture 
protons from an acidic environment, so once endocytosized into endosomes — the 
intracellular acidic ―cubicles‖ with a pH range from 4.5 to 6.5 — the buffering amines 
become protonated by binding protons inside endosomes. To replenish the losing protons, 
the symporters on endosome membranes begin to transport protons as well as chloridions 
into endosomes, and the increased concentration of chloridions triggers the inburst of water 
in order to balance the osmotic pressure. The series of events finally cause the over-swell 
of endosomes, and then endosomes break. Such mechanism can accomplish the special 
task of releasing siRNA cargoes into cytoplasm, as required by siRNA delivery systems. 
Undoubtedly, dendrimeric materials are potent candidates for delivering gene 
cargoes, however, the commonly used cationic dendrimers always associate with toxicity 
issues, including cytotoxicity, hemolytic/haematological toxicity and in vivo toxicity [24, 
41-44]. Therefore how to alleviate the toxic issue and whether dendrimeric materials are 
safe enough for therapeutic applications still remain unsolved. 
Cell penetrating peptides in siRNA delivery 
Cell penetrating peptides (CPPs) stand for a category of oligo peptides that are rich 
in basic amino acids, like arginine, lysine, and histidine, which are protonated in a 
physiological environment. CPPs are able to carry biomacromolecules to across cell 
membranes. The appearance of the arginine residue in CPPs is more frequent than other 
amino acids, and it is special because of the guanidine group on its side chain. Except the 
physiologically cationic characteristic, additionally the guanidine group can interact with 




stimulate intracellular signal pathways to change the cytoskeleton structure, resulting in 
macropinocytosis which internalizes extracellular cargoes into cells [45-47]. Thus, 
arginine-rich peptides, especially nonaarginine, have been regarded as important 
components in delivery systems for various types of cargoes. Some research groups used 
them as direct condensers of gene cargoes [48-53], while some groups modified 
independent delivery systems with arginine peptides to achieve enhanced internalization 
[54-59]. The previous results indicate that the smart utilization of CPPs may assist delivery 
systems to ―jump over‖ some key obstacles in difficult areas, such as primary cells and 
stem cells. 
Nevertheless, according to our previous results and other groups’ studies, 
nonaarginine alone failed to combine the rod-like siRNA tightly or ensure high gene 
silencing efficiency constantly [60], probably due to the dissociation of the polyelectrolyte 
particles during transfection. Similar problems may exist for other types of CPPs. As a 
result, how to use CPPs wisely and efficiently is an essential question to answer. 
1.4.3 Cardiovascular diseases and RAAS 
Cardiovascular diseases and Angiotensin II 
Cardiovascular disease (CVD) is the leading cause of death over the world. 
According to the statistics from World Health Organization (WHO), nearly 17.3 million 
people died from CVDs in 2008, and without interventions the number will increase to 
23.3 annually by the year of 2030. Over 80% of deaths due to CVDs happen in low- and 
middle-income countries, implying a severe situation for us.   




occlusion of coronary arteries due to floating atherosclerotic plaques. The blockades in 
blood vessels interrupt the supply of oxygen and nutrients immediately, and, if the 
blockades can’t be removed within 15 minutes, the cells in the infarct zone will begin to die 
and release chemotactic factors, recruiting inflammatory cells into the ischemic zone, 
followed by acute inflammation and chronic inflammation [61]. In the phase of acute 
inflammation, macrophages and neutrophils show up and activate the reactive oxygen 
system (ROS). In the phase of chronic inflammation, fibroblasts start to replace dead 
cardiomyocytes and form scar tissue in the ischemic area, causing loss of contractility. 
Eventually, ventricles undergo dilation, the ventricle wall becomes thinner, and finally 
heart failure turns to be unavoidable. Consequently, patients that survive the initial insult, 
characterized by regional loss of tissue and function have a high probability of developing 
heart failure in subsequent years. With the rising global numbers of CVDs, new treatments 
are greatly needed. 
Down to the molecular mechanism, CVDs are controlled and influenced by 
numerous factors in the ―cardiovascular continuum‖ [62, 63]. One important hormone 
system involved is the Renin-Angiotensin-Aldosterone System (RAAS), which controls 
the blood pressure and the fluid balance in the body. The activation of RAAS following 
ischemic injury initially promotes the recovery of blood pressure, but its continuous 
stimulation causes vasoconstriction, vascular and cardiac hypotrophy, and fibrosis [64]. 
Angiotensin II (Ang II), an octa-peptide hormone, which is the end-product of the RAAS, 
regulates most effects of RAAS [65]. Its overexpression following ischemic injury leads to 
cardiomyocyte death and hypertrophy, vascular smooth muscle growth, and fibrosis, all of 




heart failure [66]. Therefore, the inhibition of Ang II activation has become a common 
target for CVD therapy [67]. 
Ang II receptors 
Four plasma membrane receptors have been identified for Ang II, termed as 
Angiotensin type 1 receptor (AT1R), AT2R, AT3R, and AT4R. Most typical adverse effects 
of Ang II are mediated via AT1R, including vasoconstriction, sodium retention, 
aldosterone secretion, fibrosis, cellular proliferation, superoxide formation, inflammation, 
and thrombosis [62, 66]. AT2R is another important receptor of Ang II, but oppositely it is 
mostly considered as a protective receptor, triggering vasodilation and anti-proliferation 
effects. In adult hearts, the large amount of AT1R plays a dominant role in cardiac tissue 
[68, 69], and its RNA and protein levels further elevate to 2-3 folds after myocardial 
infarction [68, 70], causing vasoconstriction, increased cardiac contractility, myocyte 
hypertrophy, myocyte apoptosis, fibroblast proliferation, and fibrosis. This series of events 
finally lead to progressive ventricle dysfunction and heart failure. To prevent AT1R 
activation, chemical blockers for AT1R, including candesartan, eprosartan, irbesartan, 
losartan, olmesartan and telmisartan, have been studied in laboratories and in clinical trials 
as a treatment following MI and gained function improvement compared to control groups 
[71-76], and the blockade of AT1R could result in up-regulation of AT2R [22, 77], which is 
also beneficial for function preservation [78, 79]. However, it requires continuous 
treatments and sometimes results in minimal reduction in the long-term mortality. 
1.4.4 Delivery systems in cardiac tissue 




death, infiltration of immune cells, degradation of extracellular matrix (ECM), wall 
thinning, scar formation, eventually left ventricle remodeling and heart failure. With the 
identification of numerous active factors in the disease development, the direct regulation 
of the amount or the activity of these genes or proteins through the delivery strategy in 
cardiac tissue has become an attracting solution. By 2006, this area was dominated by viral 
vectors, but now an increasing number of non-viral delivery systems have shown their 
potentials.  
Delivery systems realizing the basic requirements 
The nature of cargoes determines the basic requirements for the delivery system. 
The instability against nucleases is one of the major concerns for gene drugs, especially for 
small RNA molecules, which are more sensitive to enzyme degradation. The anionic 
phosphate backbone is another obstacle to be overcome, as the repulsive electrostatic 
interaction between the nucleic acids and cell membranes impedes the gene molecules to 
diffuse freely into cells. In addition, the short lifetime of gene drugs (e.g. 5 min for siRNA 
molecules following intravenous injection) also demonstrates the need for a delivery 
system to improve the pharmacokinetic properties.  
To achieve the requirements mentioned above, various types of delivery vehicles, 
mainly polymeric materials and liposomes, have been studied to compact or load gene 
cargoes into nano-scaled particles for the delivery in cardiac tissue. The particles protect 
the integrity of nucleic acids against nuclease and also optimize their pharmacokinetics by 
the alteration of size and surface properties. Reineke et al. designed a series of 
poly(glycoamidoamine) (PGAA) materials by incorporating a carbohydrate comonomer 




tartarate-incorporated T4 glycopolymer complexed with NF-κB oligodeoxynucleotide 
(ODN) decoys showed 87% penetration of myocardium in mouse hearts and nearly 
complete reduction in Cox-2, a well-known NF-κB dependent gene in heart, with a dose of 
10.0 μg [82]. A facial amphipathic deoxycholic acid-modified PEI (1.8 kDa) (PEI1.8-DA) 
conjugate was synthesized by Kim et al. to deliver SHP-1 siRNA in a rat IR model [83], 
and the treatment decreased elevated SHP-1 expression to the normal level and 
significantly reduced the CM apoptosis and infarct size to 7.7% apoptosis index and 5.4%, 
respectively.  
Unlike gene cargoes, protein cargoes, such as growth factors, demand delivery 
systems to maintain their activities and also effective concentrations at the site of action. 
The protein activity may be insulted chemically to the primary structure due to 
metabolisms (e.g. deamidation, oxidation, beta elimination, incorrect disulfide formation, 
and racemization) or physically to the secondary or higher structures (e.g. denaturation, 
aggregation, precipitation, and surface adsorption). Matrix-type particles are able to 
protect the encapsulated protein drugs against the external attacks, and meanwhile the 
protein cargoes can diffuse from the vehicles slowly to keep the drug concentration at a 
relatively high level at the administration spot. VEGF loaded PLGA particles [84] and 
PlGF-loaded chitosan-alginate nanoparticles [85] were applied through intramyocardial 
injections in rat MI models, and both studies showed improved cardiac functions and 
angiogenesis with increased ejection fraction values and vessel densities. Except the 
matrix-type vehicles, a degradable particle can also release the loaded protein gradually via 
surface erosion or bulk degradation. Davis et al. utilized degradable polyketal particles 




increased the production of SOD in hearts and decreased the apoptosis of CMs to the same 
level as the sham group [86]. 
Micelles liposomes [87, 88], and silica particles [89-91] were also used as delivery 
systems in hearts. However, this category of delivery systems that only realized the basic 
demands are not the mainstream in cardiac applications, as the non-phagocytic CMs set up 
a high standard for the efficiency of delivery systems. 
Delivery systems improving internalization efficiency 
To improve the internalization efficiency in cardiac cells, the modification of 
additional components to the basic vehicles has become a common strategy. Cell 
penetrating peptide (CPP) is a major category of ligands in this usage, especially TAT and 
oligo-arginine (R9). The methods to incorporate CPPs into delivery vehicles are diverse, 
such as complexing with gene cargoes [92], conjugating to DNA or RNA molecules [93], 
modifying on the surface or scaffolds of liposomes or polymers, [94-96] and decorating on 
other complicated systems [97]. All the results showed that CPPs did enhance the 
internalization of delivery systems in CMs. However, CPPs promote the penetration 
through cell membranes with a non-specific manner, so the delivery systems could be 
uptake by other types of cells as well. For instance, it’s possible that the delivery vehicles 
may be grabbed by macrophages that accumulate in cardiac tissue after ischemic injury. 
To guide delivery systems into a certain type of cells, cell-type-specific ligands 
were incorporated into vehicles, including carbohydrates, peptides, proteins, etc. GlcNAc 
is a saccharide ligand specific to CMs screened out from a carbohydrate library, and its 
conjugation successfully delivered a liposome system and a polyketal system into CMs [98, 




PCM is a ligand that targets to primary CMs [100], and Bull et al. used this peptide in their 
polymeric systems to deliver siRNA in CMs in vitro [93, 95, 101]. Molecules that can 
recognize the membrane proteins of CMs constitute another type of potential ligands. For 
example, PGE-2 conjugated siRNA was used in Bull’s study to induce the 
receptor-mediated endocytosis in H9C2 cells [102]. Delivery systems guided by specific 
ligands do possess superior binding/internalization abilities in CMs compared to 
un-modified systems; however CPP-guided delivery systems still own the higher delivery 
efficiency in general. Consequently, the combination of the two types of ligands may 
become a useful method for developing delivery systems in cardiac tissue, which, in fact, 
has shown some synergic effects in transfecting CMs in vitro and in vivo [93, 95, 103, 104].  
Delivery systems targeting cardiac tissue 
Targeted delivery to the heart through a systemic administration is the ultimate 
objective of gene therapy in treating cardiovascular diseases. Three categories of strategies 
have been employed for this purpose so far, including passive targeting, facilitated 
targeting, and active targeting.  
The phenomenon of passive targeting to the heart was claimed by Uskov et al. They 
observed an increased accumulation of silica nanoparticles with diameters of 6-13 nm in 
cardiac tissue after ischemic injury compared to normal cardiac tissue [89, 90]. It could 
pave a way for delivering drugs to damaged myocardium; however the mechanism beneath 
the cardiac accumulation has not been clarified, leaving the criteria to establish such 
delivery systems un-cleared. Size of the particles may matter, but how to identify the 
appropriate range needs to be figured, since another study reported that liposomes of 




Facilitated targeting utilizes external sources to lead delivery systems reaching 
target sites. The ultrasound-targeted microbubble destruction (UTMD) is the most 
commonly used method in this area. The ultrasound energy is able to enhance the local 
vascular permeability and meanwhile destruct the gene- or protein-loaded microbubbles 
into pieces to release the cargoes on site. The delivery efficiency is dependent on time and 
ultrasound energy. Although quite a few studies have proven the efficacy of UTMD in 
animal models of MI or IR [105-109], concerns still exist regarding the transformation to 
human applications, such as the potential risk of tissue damage. Another method is to use 
the magnetic field to guide magnetic particle-incorporated systems moving to the heart. 
For instance, Ma et al. used magnetic nanobead/ adenoviral vector complexes to induce 
VEGF expression in rat hearts successfully with the facilitation of a magnetic field [110]. 
Compared to UTMD, this strategy avoids tissue damage and is easier to transform to 
human applications, yet it needs to be further developed to carry other categories of 
cargoes. 
Active targeting involves targeting ligands specific to cardiac tissue, which can be 
conjugated to established delivery systems. Ideally the targeting ligands recognize cardiac 
tissue by a specific interaction with certain receptors or markers in myocardium and 
promote the delivery vehicles to accumulate in the heart. To identify ligands targeted to 
myocardium, phage display is the common method, and at least three ligands have been 
screened out. One candidate, named as ischemic myocardium-targeted peptide (IMTP), 
was conjugated to a cystamine bisacrylamide-diamino hexane polymer with the 
modification of the R9 peptide (IMTP-CD−9R), and the intravenous injection of 




injured left ventricle tissue, showing the targeting efficacy of IMTP [103]. Instead of 
peptides screened from phage display, Kohane et al. used an Ang II sequence on liposome 
vehicles to recognize the Ang II receptors on cardiac cells, which has an increased 
expression level after ischemic injury in the heart [111]. Their results showed that the Ang 
II sequence caused a higher accumulation of liposomes in cardiac cells than the scrambled 
sequence, but no comparison between different organs was given. The risk of Ang II 
activation by the peptide sequence is another concern for the safety. 
In summary, some efficient delivery systems have been reported for cardiac tissue, 
but mostly for proteins and plasmids. Safe and efficient delivery systems for small RNA 







CHAPTER 2  
DEVELOPMENT OF A DEGRADABLE CATIONIC POLYMER TO 
SILENCE GENE EXPRESSION IN VITRO 
 
2.1 Introduction 
It is generally accepted that polymeric materials are superior to small molecule 
materials when it comes to constructing gene delivery systems, and in fact polymeric 
materials have been widely used in gene delivery for cancer cells, cell lines, primary cells, 
and stem cells. Though with great potentials, mechanisms underlying polymers’ strengths 
were not studied thoroughly. Sometimes a subtle variation could cause a significant change 
on polymers’ properties. It is important to identify the factors that matter to the transfection 
performance and figure out how to optimize the delivery systems. In this chapter, peptide 
polymers constructed from CPPs were studied as examples.   
CPPs have shown their potentials in improving the cell internalization of their 
carried cargoes in various types of cells. The most representative CPPs include TAT, a 
peptide sequence of Trans-Activator of Transcription in HIV gene, and nonaarginine, 
termed as R9. Both TAT and R9 are rich in the arginine residue. Once arginine-rich 
peptides approach cells, the guanidine groups of arginine residues interact with 
proteoglycans on cell membranes and stimulate intracellular pathways that cause 
cytoskeleton rearrangements and finally induce macropinocytosis [45-47], resulting in 
effective cell membrane penetration [112-114]. However, according to our previous results, 




possible reason is that the interaction between the short peptide and siRNA molecules is 
not strong enough, as siRNA has a rod-like structure that can hardly be condensed into tight 
particles, and the particles formed from siRNA and nonaarginine peptides are likely to 
dissociate during the transfection, leaving siRNA naked again. Since the short peptides 
don’t have strong affinities with siRNA, polymerized peptides may address the issue by 
providing more siRNA-binding sites. 
To overcome the drawbacks of the short peptides, polymerized oligo-peptides have 
been developed and applied in gene delivery. Zhang et al. studied a mild oxidation reaction 
to form disulfide bonds among peptides with cysteine residues, providing a strategy to 
synthesize peptide polymers from peptide monomers of specific sequences [115]. Seymour 
group published a series of studies of peptide polymers composed of lysine, or histidine, or 
their mixture to deliver DNA or siRNA [116-118], using positively charged lysines to 
complex nucleic acids and using histidines to induce endosome escape. Manickam 
demonstrated the usage of a polymerized TAT polymer in delivering DNA plasmids in a 
melanoma cell line [119], and Won reported the study of polymeric nonaarginine peptides 
in siRNA delivery in vivo [120]. It is no doubt that the physical and chemical properties of 
siRNA-loaded particles would be affected by the polymeric structure of peptides, however, 
there were few studies focusing on the mechanism of the improved efficiency upon 
polymerization. The mechanism of their efficiency, especially compared to their 
monomers, hasn’t been well exploited.  
Another un-clarified mechanism is that whether the modification of functional 
ligands is able to improve the delivery efficiency of polymerized peptides, and how much 




of polymerizing oligo-peptides, but no further derivation from the peptide scaffolds was 
demonstrated. For example, few detailed information on how the ligand modification 
would affect the performance of polymerized peptides was reported, which in fact is one of 
the major strategies used in targeted delivery. Whether the peptide polymers are efficient 
enough in gene delivery and how much improvement could be gained from the ligand 
conjugation need to be figured out.  
To address the unsolved issues, in this chapter we developed oligo-arginine based 
polymeric materials by polymerization with degradable linkages and modifications of a 
targeting ligand. Unlike the traditional methods of polymer synthesis by adding monomers 
at the terminal of intermediate products step by step, our materials were synthesized by 
monomer assemblies in a mild reaction environment, and the molecular weight was 
controlled by the reaction time. Using this method, it is easier to adjust the properties of the 
peptide polymer by altering the structure and composition of the monomer. In this study, 
we used the RGD short peptide as a targeting ligand to improve siRNA delivery efficiency 
in lung cancer cells and liver cancer cells. 
2.2 Results 
Synthesis of dPOA polymer 
The scheme of synthesis of the degradable poly(oligo-arginine) (dPOA) polymer 
was illustrated in Figure 2.1. The molecular weight of dPOA ((CR9C)n), determined by gel 
permeation chromatography (GPC), was about 140 KDa with a dispersive coefficient of 
1.154. To assess the advantages of the peptide polymers toward the short peptide monomer, 




used for comparison in experiments below. The other dPOA (CR9KC)n was synthesized 
following the same method, and the molecular weight of the obtained (CR9KC)n was 
around 58 KDa with a dispersive coefficient of 3.8. RGD ligands were conjugated to the 
exposed primary amines on (CR9KC)n, and H
1
-NMR spectrum showed that about 15% of 




Formation of siRNA- loaded arginine peptide particles 
Gene Finder exclusive assay was employed for the detection of the formation of 
siRNA-loaded arginine peptide particles. The decline in the fluorescent intensity indicated 
to which degree siRNA was complexed by arginine peptides, as only the dye molecules 
combined with free nucleic acids give strong signals, and the dye molecules would be 
discarded from siRNA after complexation. With the N/P ratios increased from 3 to 20, the 
fluorescent intensity of the samples of siRNA-loaded particles dropped quickly till reached 
a plateau (Figure 2.2), showing arginine peptides’ capability of combining siRNA. At N/P 
=10, 53% of siRNA still remained un-loaded in the R9 group, while only around 20% of 
free siRNA existed in arginine polymer groups. Among the three peptide materials, dPOA 
and PLR showed stronger capabilities in complexing siRNA than R9, which indicated that 
Figure 2.1 Scheme of the synthesis of dPOA. Monomers of CR9C were reacted 




polymeric peptides own higher siRNA loading efficiencies than the oligo peptide when the 




Particle size and zeta-potential 
Particle sizes and zeta-potentials were determined for siRNA-loaded arginine 
peptide particles. While R9 failed to form stable particles with siRNA at the low N/P ratios, 
as they were undetectable by light scattering, the diameters of dPOA/siRNA particles were 
208.4 ± 4.8 nm and 190.0 ± 2.6 nm at N/P ratios of 3 and 5, respectively. On the other hand, 
when arginine peptides were mixed with siRNA under the same N/P ratios, the 
zeta-potentials of R9/siRNA particles varied from -4.4 to +2.3 mV among triplicates, while 
dPOA/siRNA particles showed higher and relatively consistent zeta-potentials of around 
+7mV (Figure 2.3).  
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Figure 2.2 siRNA loading capacity of arginine peptides assessed by fluorescent 
dye exclusive assay. The amount of free siRNA decreased with increasing N/P 
ratios, indicating the formation of siRNA-loaded arginine peptide particles. Values 
are mean±SEM after normalizing fluorescent intensities of samples to that of a 








siRNA stability against RNase treatment 
To evaluate arginine peptides’ abilities of protecting siRNA, siRNA-loaded 
arginine peptide particles were treated with RNase at 37 °C for 30 min until naked siRNA 
was completely degraded. siRNA was released from the particles by polyacrylic acid 
(PAA), a polyanionic reagent capable of competing with siRNA in combining cationic 
materials, and escaped siRNA was detected by gel electrophoresis to assess the integrity. It 
was found that the siRNA loaded with R9 completely disappeared, while the siRNA loaded 
with dPOA and PLR was still detectable (Figure 2.4), indicating that the polymeric 
structure is able to enhance the interaction between siRNA and peptides and further 
increase the stability of siRNA-loaded particles.  
Figure 2.3 Zeta-potentials of R9/siRNA and dPOA/siRNA complexes at N/P=3 
and N/P=5. The Zeta-potentials of dPOA/siRNA complexes were significantly 
higher than those of R9/siRNA at the same N/P ratios. Values are mean±SEM. 








To determine the capability of arginine peptides of releasing siRNA in cytoplasm, 
dPOA/siRNA and PLR/siRNA particles were treated by glutathione (GSH) for 30 min at 
37°C, and the released siRNA was detected and compared by gel electrophoresis. The gel 
showed that siRNA was released quickly from dPOA particles, especially at low N/P ratios, 
as clear siRNA bands were detected after GSH treatment, but no siRNA was observed 
released from the particles made from the unreducible PLR (Figure 2.5). 
Figure 2.4 Nuclease resistance of siRNA-loaded arginine peptide particles. 
siRNA-loaded particles at N/P ratios of 3 and 5 were treated with RNase until naked 
siRNA was degraded completely. The integrity of released siRNA was detected by 
electrophoresis. siRNA bands only showed in dPOA and PLR groups. Samples 







The cytotoxicity of arginine peptides was determined by MTS assay after 6 h 
incubation. Significant cytotoxicity was observed for the unreducible PLR at the 
concentrations above 10 μg/ml, while R9 and dPOA had minimal effects to the cell 
viability within the tested concentration range (Figure 2.6), and all groups maintained cell 
viabilities above 80%.  
 
 
Figure 2.5 GSH treatment for dPOA/siRNA and PLR/siRNA complexes. (a) 
Before GSH treatment, siRNA were loaded completely by dPOA or PLR at various 
N/P ratios. (b) After treated with GSH for 30 min, siRNA bands were observed in 






Fluorescence microscopy and flow cytometry analysis 
To observe the siRNA distribution and internalization efficacy, cy3-labeled siRNA 
was complexed with R9 and dPOA, respectively, and incubated with A549-luci cells for 6 
h, followed by fluorescence microscopy observation and flow cytometry analysis. Cells 
treated with dPOA/siRNA particles showed stronger fluorescent signals than those with R9 
/siRNA particles (Figure 2.7a). 51.6% and 83.7% of cells treated with dPOA/cy3-siRNA 
were tested fluorescent positive by flow cytometry at N/P ratios of 3 and 5, respectively, 
while the percentages in R9 group were 7.49% and 25.0% (Figure 2.7b), which 
corresponded with our observation under fluorescence microscopy. 
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Figure 2.6 Cytotoxicity of arginine peptides. PLR exhibited a significant 
concentration-dependent cytotoxicity in the tested concentration range, while 








siRNA delivery efficiency of dPOA and RGD-g-dPOA 
At a siRNA concentration of 100 nM, dPOA/siRNA particles tended to induce 
stronger gene silencing effects in A549-luci cells than R9/siRNA particles at 24, 48, and 72 
h after transfection, but not to a significant degree. To further enhance the delivery 
efficiency of dPOA, a short peptide ligand RGD was conjugated to the synthesized 
(CR9KC)n to a conjugation level of 15%, termed as RGD-g-dPOA. Both (CR9KC)n 
dPOA and RGD-g-dPOA showed no significant cytotoxicity to cells (Figure 2.8) with cell 
viabilities above 90% at all tested concentrations. 
 
Figure 2.7 Fluorescence microscopy observation and flow cytometry analysis 
of cy3-siRNA loaded particles. (a) Cy3-labeled siRNA (red) was delivered to 
A549 cells by R9 and dPOA, respectively, at N/P=3 and 5. (b) Quantization of 
fluorescent cells by flow cytometry. In both results, dPOA/siRNA group showed 




















In A549-luci cells, RGD-g-dPOA/siRNA particles decreased the luciferase 
expression levels to 65.4 ± 3.3%, 54.4 ± 2.8%, 48.5 ± 3.5%, and 42.9 ± 2.0% at N/P ratios 
of 10, 20, 30, and 40, which were 76.6 ± 8.5%, 79.3 ± 2.1%, 71.8 ± 12.3%, and 56.2 ± 8.6% 
in the dPOA/siRNA treatment groups (Figure 2.9a). There was a significant difference at 
the N/P ratio of 20 (P<0.01). In HepG2 cells, the luciferase expression levels were 118.6 ± 
15.8%, 64.2 ± 9.6%, 60.9 ± 7.4%, and 55.3 ± 11.6% at N/P ratios of 10, 20, 30, and 40, 
respectively, upon RGD-g-dPOA/siRNA treatment, and at N/P ratios of 30 (P<0.05) and 40 
(P<0.01) the expression levels were significantly lower than those with dPOA/siRNA 
particles (Figure 2.9b).  
 
Figure 2.8 Cell viability upon the treatment of dPOA and RGD-g-dPOA. Both 
peptide polymers showed minimal cytotoxicity to A549 cells with cell viabilities 







Arginine rich peptides have been widely used in delivering various types of cargoes, 
including proteins, plasmids, oligonucleotides, liposomes, etc [121, 122]. In siRNA 
delivery, some groups used arginine peptides or their derivations to directly combine 
siRNA for delivery, such as nonaarginine [50], stearylated octaarginine [48], targeting 
ligand conjugated nonaarginine [49, 52, 53], pentadecaarginine [52], and poly-L-arginine 
[51]. Though with some positive results, particles formed from the oligo-arginine peptide 
and siRNA are usually not stable enough against the serum and nucleases, which was also 
verified by our results, as the electrostatic interaction between these two small molecules is 
hardly strong. In this study, we used an oxidative polycondensation method to synthesize 
polymeric arginine peptides, allowing stronger interactions with siRNA. Polymeric 















Figure 2.9 Gene silencing efficiency of siRNA-loaded dPOA particles and 
siRNA-loaded RGD-d-dPOA particles in A549-luci (a) and HepG2 (b) cells. 
Values are mean±SEM after normalizing to the luciferase expression level of the 
untreated control. In most transfection groups, siRNA-loaded RGD-g-dPOA 
particles tended to induce higher gene silencing effects against luciferase than the 
siRNA-loaded dPOA particles. The difference reached statistical significances at 
N/P=20 in A549-luci cells and N/P=30 and 40 in HepG2 cells. n=3~4. *P<0.05, ** 





required amount of delivery materials for a given dose of siRNA. Lowering dosage is very 
important for the real clinical usage, regarding the economic cost, manufacture technology, 
and patient tolerance. The zeta-potential data also showed the significant distinction 
between R9 and dPOA materials. The consistency of zeta-potentials of dPOA/siRNA 
triplicates indicated the better homogeneousness among particles than R9/siRNA, and 
meanwhile the higher values of zeta-potentials implied dPOA/siRNA particles presented 
more positive charges on the particle surface at the same N/P ratio. Accordingly, the high 
positive surface potential enhanced cell uptake by non-specific interactions with cell 
membranes, resulting in the better performance of dPOA in delivering siRNA than the 
oligo-arginine peptide.  
To further improve the transfection efficiency of dPOA, we conjugated the RGD 
peptide to the dPOA backbone. RGD is a bioactive ligand that can bind to 11 types of 
integrins on cell membranes, so it has been widely used for improving the efficacy of 
delivery systems [123-125]. In our study, the RGD ligation enhanced gene silencing effects 
both in the lung cancer cell line and liver cancer cell line, especially at high N/P ratios. 
Higher N/P ratios mean the number of RGD ligands in a particle is more than that at low 
N/P ratios. This may be a sign implying that a certain density of ligands is needed to fully 
realize the ligand function. Here dPOA provided a platform for the ligand modification, 
and a tunable modification of ligands could be achieved by adjusting the ratio between 
ligands and dPOA. Various ligands could be modified on dPOA, including stabilizing 
ligands, targeting ligands, fusion ligands, and internalization-improving ligands, to make 
the design obtain comprehensive and optimized functions and properties. 




but the problems on their safety issue haven’t been solved. A considerable body of studies 
reported that the toxicity of cationic polymers or dendrimers is associated with their 
molecular weights and generations, such as PLL, PEI, and PAMAM. One strategy to 
reduce such cytotoxicity is the degradable design, and it has been applied to various 
cationic materials, such as PEI [126-130]. In our study, we used the disulfide bond, a 
reducible bond in the cytoplasmic environment, to link oligo-arginine peptides (with two 
cysteine terminals) to form a linear arginine peptide polymer. Compared to the unreducible 
commercial PLR peptide, dPOA showed a significantly lower cytotoxicity in A549 cells. It 
is worth noting that the influence of dPOA to cells was very similar to that of R9, which 
could be an indirect evidence for the degradability of dPOA in cytoplasm, and such 
degradability is the main reason of the decreased cytotoxicity of cationic polymers. 
Meanwhile, disulfide bonds also tended to increase the solubility of the polyarginine. In 
our experiments did commercial PLR tend to form visible precipitations in the phosphate 
buffer, and it was also reported to precipitate proteins in serum [112], but dPOA showed no 
similar drawback. Besides the lowered cytotoxicity and increased solubility, the cleavage 
of disulfide bonds in cytoplasm guaranteed the siRNA release from particles to initiate 
RNAi process. In fact, too condensed particles, like PLR/siRNA, do not benefit 
transfection. 
As to the comparison of our study to other published data, R9 [50] and R15 [52] 
were reported to have the capability to deliver siRNA into mammalian cells, but in our 
study they failed to exhibit substantial functions in improving cell uptake and further gene 
silencing. One possible reason is that we used R9 at N/P ratios lower than the other groups 




high enough to overcome the repulsive force from cell membranes. Another possible 
reason is due to the difference between cell lines. Wang et al. reported to use R9 in siRNA 
delivery to human gastric carcinoma cells but not A549 cells, although they evaluated the 
cytotoxicity of R9 in A549 cells. Kim’s study pointed out that R9/siRNA particles didn’t 
lead to significant gene silencing effects in 293T cells [60]. Probably different cell types 
have different preferences for endocytosized particles, such as their sizes and surface 
potentials, and such preferences may be the crucial factors in the non-specific endocytosis. 
For further improvements, the ligand-receptor mediated endocytosis could be used to 
promote cell internalization, by grafting receptor-specific ligands on the reducible arginine 
backbone, for instance. The reducible arginine peptide polymer has the potential to become 





CHAPTER 3  
DEVELOPMENT OF A NEUTRAL CROSSLINKED DENDRIMERIC 
SYSTEM TO SILENCE GENE EXPRESSION IN VITRO 
 
3.1 Introduction 
Most investigations of non-viral siRNA delivery systems mainly focused on 
cationic carriers [131], such as polymers, lipids and peptides, the materials that can form 
siRNA-loaded vehicles based on electrostatic interactions under the physiological 
environment. Among the established cationic delivery systems, dendrimers are the 
shining stars. A typical dendrimer is composed of three components: the core, the 
branches, and the peripherals. Dendrimer molecules have tunable structures, as the 
number of branches and peripherals can be controlled by the growth of generations. 
Cationic dendrimers can have strong charge interactions with siRNA when the generation 
of dendrimers is relatively high with rich positive charges presented on the surface, and 
the high affinity prevents the particles from dissociation during transfection. Dendrimers 
also provide the sites for ligand modifications with high possibilities of inducing 
multivalent interactions, especially for saccharide ligands. This property endows 
dendrimeric materials a great power to target specific cells and enhance cell 
internalization. Another important advantage of dendrimers is the endosome escape 
ability due to the buffering amines at the joint points in the structure, which allows the 
siRNA release into cytoplasm. Consequently, the nature of cationic dendrimers is suitable 




However, cationic dendrimers bear the similar inherent disadvantages as other 
cationic systems, possibly even worse due to the high-density charges on the surface. For 
one thing, cations on dendrimers such as the protonated primary amines easily cause 
toxicity, resulting from the membrane damage, apoptosis pathway activation, and 
medium depletion [23-26]. The toxicity of dendrimers is dependent on the generation and 
molecular weight, as the two parameters determine the number of primary amines on the 
dendrimer surface. Once the dendrimer surface is substituted with neutral or anionic 
groups, the toxicity decreases significantly [26, 132-134]. Also dissociation and 
deformation may happen for polyelectrolyte complexes, because the pure electrostatic 
interaction can hardly last for a long time, and the aggregation between the 
polyelectrolyte particles may also happen. For example, the size of polypropyleneimine 
(PPI)/siRNA was reported to change from 150 ± 22.2 nm to 612.7 ± 45.1 nm during the 
48 h in PBS buffer [135], indicating that the particles went through structural changes. 
Possibly variations in the ionic strength and shear stress may further influence the 
properties and performance of polyelectrolyte vehicles [136-139]. In addition, since little 
knowledge has been obtained on how to control electrostatic interactions to maintain or 
terminate the integrity of polyelectrolyte particles, the timing of siRNA release from 
polyelectrolyte complexes is unpredictable and uncontrollable, which means the siRNA 
is possible to be released before reaching the cytoplasm.  
In this chapter, we established a neutral crosslinked system which provides 
stability, safety and controllability for siRNA delivery. The basic idea is to utilize other 
components in the delivery system to replace the role of primary amines. Traditionally, 




interacting with cell membranes. All of the three tasks relate with the charge property of 
primary amines. Since the pKa of tertiary amines is below 7.4, meaning that they could 
be protonated temporarily at a low pH environment, tertiary amines were used as the 
temporary source of positive charges and to load siRNA in this system. A crosslinking 
method was introduced into the system to stabilize the particles, and meanwhile the 
crosslinking bond was designed to be reversible at low pH, like the endosomal 
environment, to guarantee the controllable siRNA release. To enhance the interaction 
with cells and meanwhile reduce the endocytosis by unspecific cells, the neutral 
dendrimers were further modified with targeting ligands. This new rational created a low 
toxic, stable, and targeted delivery system for siRNA. 
 We used the commonly used cationic dendrimer polyamido amine (PAMAM) as 
a model molecule to test our idea. The primary amines on PAMAM surface were 
replaced by neutral crosslinkable hydrazide groups so as to produce the neutral dendrimer, 
and saccharide ligands were modified to improve the cell targeting. Saccharide ligands 
were chosen here because they are biocompatible, bioactive, and most importantly, they 
exert multivalent interactions with membrane receptors when modified on the dendrimer 
surface. Glutaraldehyde was selected to be the crosslinker, since the hydrazone bond 
formed by glutaraldehyde and hydrazide is reversible and cleavable in a certain condition, 
which could endow the system with degradability and the controlled release mechanism. 
Based on the crosslinking methodology, factors that control the properties of the 





Synthesis of neutral PAMAM-HYD and saccharide-modified PAMAM-HYD 
To obtain saccharide-modified neutral dendrimers, G4.0 PAMAM was first 
expanded to G4.5 by reacting with methyl acrylate, and the G4.5 PAMAM was further 
modified with hydrazide groups on the surface. The obtained products with theoretically 
128 hydrazide groups were termed as PAMAM-HYD. To add the cell targeting capacity, 
saccharide ligands were modified on PAMAM-HYD. The tested ligands included 
mannose, glucose, GlcNAc, lactose, galactose, and GalNAc. Figure 3.2 showed the 
structure of GalNAc-PAMAM-HYD as an example of the saccharide-modified 
PAMAM-HYD. All the saccharide-modified PAMAM-HYDs have reached the saturate 
modification levels from 45%- 52% as described in literature [40]. 
Identification of the targeting ligand for HepG2 cells 
To study the interaction between neutral dendrimers and cells, different 
saccharide-modified PAMAM-HYDs were labeled with fluorescein and then incubated 
with HepG2 cells to understand the cell binding and cell uptaking properties. Figure 3.1 







Among the tested saccharide-modified dendrimers, Gal-, GalNAc-, Lac- and 
GlcNAc-PAMAM-HYD showed much stronger fluorescent signals in HepG2 cells than 
other dendrimer materials, indicating the high avidity of these saccharide molecules 
toward HepG2 cells. GalNAc-PAMAM-HYD showed the strongest fluorescent intensity 
on a per cell basis, and more than 99% of cells were detected fluorescent-positive. 
Therefore, GalNAc was identified as the most efficient targeting ligand to HepG2 cells, 
which accorded with literatures, and was used for the further material development.  
Development of the neutral crosslinked system 
Figure 3.2a illustrated the chemical structure of the saccharide-modified 
dendrimer GalNAc-PAMAM-HYD (GPH). By controlling the feed ratio of GalNAc to 
PAMAM-HYD in the modification reaction, GPHs with varied GalNAc modification 
levels were obtained. The average GalNAc modification levels were 11.8%, 18.4% and 
31.5%, calculated from the H
1
-NMR analysis (Figure 3.2b), and the corresponding 
Figure 3.1 Flow cytometry analysis of binding and internalization efficiency 
of different saccharide-modified PAMAM-HYDs with HepG2 cells. Glu-, 
Man-, Gal-, GalNAc-, Lac- and GlcNAc-PAMAMs and PAMAM-HYD were 
labeled with fluorescein and treated with HepG2 cells. Gal, GlcNAc, Lac, and 
GalNAc showed their abilities to enhance the interaction between dendrimers and 
HepG2 cells, and GalNAc-PAMAM-HYD showed the strongest cell 





dendrimers were named as GPH-15, GPH-23 and GPH-40, respectively, with the number 




 A scheme for preparing siRNA-loaded crosslinked particles was shown in Figure 
3.3. Since the hydrazide group has a pKa value below 7 [140-143], the PAMAM-HYD 
and GPHs are expected to be neutral at the physiological pH. On the other hand, as the 
pKa of tertiary amines was reported between 6 and 7 [144-146], the tertiary amines own 
the buffering capacity of absorbing protons under the acidic condition. This property 
allows PAMAM-HYD and GPHs to become internally cationic to bind siRNA within a 
Figure 3.2 Structure of the neutral dendrimer of GalNAc-PAMAM-HYD 
(GPH) (a) and the H
1
-NMR spectrum of GPHs with varied GalNAc 
modifications (b). The peripheral amines were substituted with physiologically 
neutral hydrazide groups and bioactive GalNAc in GPHs. The average numbers 
of modified GalNAc in each GPH were calculated to be 15, 23, and 40, 
respectively, according to the H
1
-NMR results ( δ 2.1 (-CH3CONH- of GalNAc 
moiety, 3H), δ2.6 (–NCH2CH2CO– of PAMAM-HYD scaffold, 504H)). Adapted 












Complexation of siRNA with PAMAM-HYD and GPHs at acidic and neutral conditions 
To determine whether siRNA was complexed with PAMAM-HYD or GPHs via 
the internally charged tertiary amines as expected, the Gene Finder exclusive assay was 
conducted at both neutral and low pHs. At pH 5.0 the amount of free siRNA in solutions 
gradually decreased with the increasing amount of PAMAM-HYD or GPHs, and the 
original fluorescent intensity exerted from siRNA-bound Gene Finder decreased to below 
Figure 3.3 Schematic process of preparing siRNA loaded crosslinked 
particles for siRNA delivery. The whole process includes the mixing of siRNA 
and neutral dendrimers at pH 5.0, adding the crosslinker, blocking unreacted 
crosslinkers, recovering the pH to 7.4, and dialysis. Adapted with permission 





10% when the molar ratio between dendrimers and siRNA (D/S)  reached 3.5 (Figure 
3.4). In addition, the GalNAc modification didn’t affect the step of siRNA combining 
with neutral dendrimers at pH 5.0, as the siRNA loading capacities of different GPHs 
showed no significant distinction. On the other hand, PAMAM-HYD and GPHs didn’t 




To clearly compare the charge properties at different pHs, zeta-potential 
measurements were conducted for the dendrimer-siRNA mixtures. The binary mixtures 
of dendrimers and siRNA possessed positive potentials at pH5.0, ranging from 12 to 
15mV (Figure 3.5), while all mixtures had negative potentials when mixed at pH7.4. 
 
Figure 3.4 Complexation of siRNA with PAMAM-HYD and GPH 
dendrimers at pH 5.0 and pH 7.4. At pH 5.0, the amount of unloaded siRNA 
decreased with increasing amount of PAMAM-HYD or GPHs, while at pH7.4, the 
amount of unloaded siRNA didn’t change at any ratio between dendrimers and 
siRNA. Adapted with permission from Liu (2012) [185]. Copyright (2012) 







Preparation of siRNA-loaded crosslinked particles 
To construct siRNA-loaded crosslinked particles, glutaraldehyde was added into 
the mixture of PAMAM-HYD and siRNA at pH5.0 to immobilize the temporarily formed 
polyelectrolyte parties by establishing linkages between the hydrazide groups on the 
dendrimer surface. Theoretically, the siRNA and PAMAM-HYD would electrostatically 
assemble complexes first, followed by crosslinking via glutaraldehyde. Two methods 
were used simultaneously to terminate the crosslinking reaction: recovering the pH to the 
physiological condition via buffer exchange and blocking the unreacted glutaraldehyde 
residues by adding excessive ADHs. Gel electrophoresis was used to detect unloaded 
siRNA in the systems. When the D/S ratio was settled at 1.7, the amount of unloaded 
siRNA kept decreasing with increasing concentrations of glutaraldehyde, which means 
the crosslinking reaction was involved in siRNA encapsulation (Figure 3.6). In contrast, 
Figure 3.5 Zeta-potentials of dendrimer-siRNA mixtures. All the binary 
mixtures exhibited positive zeta-potentials above 10 mV at pH 5.0 but showed 
slightly negative zeta-potentials around -3 to -6 mV at pH 7.4. Values are 
presented as mean ± SEM, n=3. Adapted with permission from Liu (2012) [185]. 





unlike the situation at pH5.0, the siRNA bands remained visible in the gel after mixed 
with dendrimers and glutaraldehyde at pH 7.4 following the same protocol (Figure 3.6). 
 
 
Similar experiments were conducted with the GalNAc-modified dendrimers so as 
to test if the method could be used to prepare siRNA-loaded particles after the ligand 
modification on neutral dendrimers. According to the experiment with Gene Finder, the 
average siRNA loading efficiencies of PAMAM-HYD and GPHs particles were 
calculated to be in the range from 79 % to 94 % (Figure 3.7). It showed that at a fixed 
molar ratio among siRNA, dendrimer, and crosslinker, the siRNA loading efficiency 
decreased with the increasing GalNAc modification, which is probably due to the 
Figure 3.6 siRNA encapsulation efficiency in the crosslinked systems. The 
amount of encapsulated siRNA increased at pH 5.0 when the glutaraldehyde 
concentrations were rising in the range from 0.17 mM to 83 mM, but at pH 7.4 
no significant siRNA encapsulation was observed in the gel electrophoresis. 










Size and zeta-potential characterization 
The measurement of the size of different crosslinked particles could be helpful to 
understand how the particle diameters vary with the crosslinker concentration and the 
surface modification of the dendrimer carriers. Again we found the particle size was also 
dependent on both the crosslinker concentration and the ligand density. Figure 3.8 
showed how the particle size changed with these two parameters. Both nano- and 
micro-scaled particles were obtained from the crosslinked PAMAM-HYD systems. The 
largest diameter was achieved up to 4.2 μm at a medial concentration of glutaraldehyde, 
Figure 3.7 siRNA encapsulation efficiency in crosslinked particles made 
from GPHs with varied GalNAc modification levels. Slightly increasing 
amount of siRNA were left unloaded when the GalNAc modification levels 
increased, indicated by the gel electrophoresis (a). According to the quantitative 
examination by Gene Finder, the siRNA encapsulation efficiency in 
PAMAM-HYD, GPH-15, GPH-23, and GPH-40 particles were 93.6 ± 0.3%, 88.4 
± 1.4%, 87.0 ± 3.8%, and 79.3 ± 1.2%, respectively. Values are mean ± SEM. 
n=3, *P<0.05, One-way ANOVA followed by the Newman-Keuls post-test. 







and the particle size declined to about 230 nm when the glutaraldehyde concentration was 
further increased. When the molar ratio between dendrimer, siRNA, and glutaraldehyde 
was fixed, the particle size decreased with the increasing GalNAc modification levels on 
the dendrimers, and the crosslinked GPH-23 and GPH-40 particles exhibited small sizes 




All the siRNA- loaded particles made from PAMAM-HYD and GPHs were 
neutral or slightly negatively charged within -3 mV at pH 7.4, detected in the 
zeta-potential measurement. In contrast, the polyelectrolyte particles made from cationic 
G5.0 PAMAM and siRNA showed a highly positive zeta-potential around 21 mV (Figure 
3.9). Therefore, the siRNA-loaded crosslinked particles can be regarded as neutral 
vehicles in the physiological environment. 
Figure 3.8 Sizes of the siRNA loaded crosslinked particles at varied 
glutaraldehyde concentrations (a) and GalNAc modification levels (b). Within 
the glutaraldehyde concentrations ranged from 0.83 mM to 833 mM, the particles 
reached a largest size of 4.2 μm at 8.3 mM and a smallest size of 230 nm at 833 
mM. At the glutaraldehyde concentration of 8.3 mM, the particle size decreased 
with the increasing GalNAc modification level to around 200 nm in GPH-23 and 
GPH-40 particles. Adapted with permission from Liu (2012) [185]. Copyright 









Stability of crosslinked particles in aqueous environment 
To assess the stability of the crosslinked particles, sizes of the GPH particles were 
monitored for 24 h in PBS buffer after the particle formulation. At the time points of 4 h 
and 24 h, the sizes and distributions of GPH-23 particles and GPH-40 particles barely 
changed over the time (Figure 3.10). Taking the GPH-23 particle as an instance, the 
average radius decreased only slightly from 122 nm to 111 nm after 24 h incubation in 
PBS buffer. In contrast, the polyelectrolyte complexes formed by siRNA and cationic 
G5.0 PAMAM went through a significant change in the size and distribution, with 
average diameters collapsing from 386 nm to 124 nm.   
 
Figure 3.9 Zeta-potentials of siRNA-loaded crosslinked particles. All siRNA 
loaded crosslinked particles made from neutral dendrimers exhibited slightly 
negative zeta-potential in the range from 0 to -3 mV. In contrast, the siRNA loaded 
polyelectrolyte particles made from G5.0 PAMAM had a high positive 
zeta-potential of 21 mV. Adapted with permission from Liu (2012) [185]. 







SiRNA release in the acidic environment 
Glutaraldehyde was chosen to be the crosslinker in this system because the 
formed hydrazone bonds between aldehyde and hydrazide are reversible, which can 
cleaved at an acidic condition. To verify the feasibility of the design, the crosslinked 
particles were incubated at pH 6.0 and pH 7.4 for 3 h, respectively, and the particles were 
detected by gel electrophoresis. The gel showed that siRNA was released from particles 
at pH 6.0 after 3 h incubation but remained inside the particles at pH 7.4 (Figure 3.11). 
This result indicated the controllable release mechanism of the crosslinked particles, 
implying the degradability of the delivery system under the specific condition.  
a b 
Figure 3.10 Size distribution of siRNA loaded crosslinked particles and 
polyelectrolyte particles. In both GPH-23 and GPH-40 crosslinked particle 
samples, no significant variation was observed for the size and distribution of the 
crosslinked particles at 4 h and 24 h after formulation, while the polyelectrolyte 
particles made from G5.0 PAMAM showed a shift of the distribution of particle 








To determine the safety of the neutral dendrimers, MTS assay was conducted. 
After incubation with dendrimeric materials for 24 h, above 80% of HepG2 cells 
remained viable after PAMAM-HYD treatment up to the concentration of 90 nmol/ml, 
while G5.0 PAMAM induced increasingly severe cytotoxicity with the rising 
concentrations. A similar pattern was observed when they were tested on the primary 
human umbilical vein endothelial cells (HUVEC) cells (Figure 3.12b). As to the 
transfection condition, no significant cytotoxicity was observed, and above 95% of cells 
maintained alive after the treatment of siRNA-loaded crosslinked particles (Figure 3.13).  
 
Figure 3.11 siRNA release from the crosslinked particles at the acidic 
condition. At pH 6.0, siRNA bands were showed in the crosslinked particle 
samples, while at pH 7.4 siRNA remained encapsulated in the particles, indicative 









Figure 3.13 Cytotoxicity of siRNA loaded crosslinked particles in HepG2 cells. 
The crosslinked particles made from PAMAM-HYD and GPHs didn’t affect the 
cell viability of HepG2 cells after 48 h incubation, and all treatment groups had 
cell viabilities above 90%. Values are mean ± SEM. n=3. Adapted with permission 
from Liu (2012) [185]. Copyright (2012) American Chemical Society. 
 
Figure 3.12 Cytotoxicity of neutral dendrimer PAMAM-HYD and cationic 
dendrimer G5.0 PAMAM on HepG2 cells (a) and HUVECs (b) after 24 h 
incubation. In both two types of cells, PAMAM-HYD showed minimal effects on 
the cell viability, while G5.0 PAMAM caused severe cytotoxicity that decreased 
the cell viabilities below 30%. Adapted with permission from Liu (2012) [185]. 






siRNA-loaded crosslinked particles were used to treat HepG2 cells at a siRNA 
concentration of 50 nM in DMEM medium containing 10% serum. Upon the siRNA 
delivery against luciferase, the luciferase expression levels decreased in the GPH-15, 
GPH-23, and Lipofectamine 2000 groups (Figure 3.14). The GPH-23 particles obtained 
the strongest silencing effect of nearly 60% knockdown of the target gene, which was 
even more efficient than the commercial reagent Lipofectamine 2000. When loaded with 
scrambled siRNA, no down-regulation of luciferase was observed with any neutral 




To visualize the internalization of neutral dendrimers, PAMAM-HYD and GPHs 
were labeled with fluorescein, and the cellular uptake of neutral dendrimers was 
examined via fluorescence microscopy. Fluorescent signal was barely observed in the 
Figure 3.14 Gene silencing effect of the siRNA loaded crosslinked particles. In 
the serum-containing medium, GPH-23 crosslinked particles showed higher 
delivery efficiency than the positive control lipofectamine, with a gene 
down-regulation around 60%. Values are mean ± SEM, n=4, **P<0.01, One-way 
ANOVA followed by the Newman-Keuls post-test. Adapted with permission from 





PAMAM-HYD group, but more HepG2 cells were fluorescent-positive in the GPH-23 
and GPH-40 treated groups (Figure 3.15a-d). To detect the internalization of the 
siRNA-loaded crosslinked particles, cy3-siRNA was encapsulated by PAMAM-HYD and 
GPH materials. PAMAM-HYD particle group only showed some scattered fluorescent 
spots, while GPH particle groups showed more even distribution of fluorescent signals in 
HepG2 cells (Figure 3.15e-h). Among all the groups, GPH-23 crosslinked particles 
seemed to have the highest siRNA internalization in cells, which was expected according 
to the gene silencing results.  
 
Figure 3.15 Cellular internalization of neutral dendrimers (a-d) and siRNA 
loaded crosslinked particles (e-h). GPH-23 and GPH-40 dendrimers showed 
visually higher rates of cell uptake in HepG2 cells, and the siRNA internalization 
rates of these two types of crosslinked particles were also observed higher than 
those made from PAMAM-HYD and GPH-15. Adapted with permission from Liu 






The design of the neutral dendrimer promotes the translation of synthetic carriers 
into the real practice. Although cationic materials remain the main fashion to fabricate 
delivery systems for gene therapy, the safety issue is always a concern when it comes to 
the translation into clinical use. Cytotoxicity, hemolytic/haematological toxicity and in 
vivo toxicity have been reported in dendrimer-related studies due to the cationic amines 
on the dendrimer surface. Acetylation of the dendrimer surface to block positive charges 
was attempted previously [147]; however, this strategy could not address the toxicity 
issue without compromising the siRNA-binding and delivery capabilities. In this study, 
the neutral crosslinked system provided a new concept of utilizing primary-amine-free 
materials. Since it were the tertiary amines that take charge of combining siRNA and the 
surface saccharide ligands that enhance the cell internalization, the substitution of 
primary amines didn’t compromise the transfection efficiency of dendrimeric materials. 
The utilization of buffering amines instead of permanently cationic primary 
amines to load siRNA is one of the unique features of the new system in this part. The 
physiologically neutral dendrimers, PAMAM-HYD and GPHs, own two possible sites for 
protonation, the internal tertiary amines and surface hydrazide groups. The pKa of the 
tertiary amines within the interior branches of PAMAM dendrimers was reported 
between 6 and 7 [144-146], while that of carboxylic hydrazide groups was reported down 
to 3.6 [142]. Consequently, most surface hydrazide groups in neutral dendrimers may 
remain unprotonated at pH 5.0, and the interaction between siRNA and PAMAM-HYD 
or GPHs mostly depends on the internally charged tertiary amines. This hypothesis was 




in which GPHs with different saccharide modification levels didn’t show a significant 
difference in binding siRNA at all tested D/S ratios. Previous studies on PAMAMs 
owning neutralized groups on the surface also support the conclusion that dendrimers are 
capable of interacting with nucleic acids or anionic drugs through the internally charged 
amines [148-150]. 
The method of crosslinking was the foundation of the siRNA-loaded neutral 
particles. Crosslinked systems were previously developed to increase the stability of 
polyelectrolyte particles made from cationic delivery materials [135, 137, 138, 151-155]. 
Particularly, the sizes of polyelectrolyte particles made from siRNA and cationic 
PAMAM were observed kept growing within the 72 h after formulation, while a 
crosslinking reaction preserved the original size to some degree [156]. In our neutral 
crosslinked system, the capability of maintaining the morphology of particles was 
verified again for the crosslinking method, significantly distinct from the un-crosslinked 
system. The crosslinking strategy did not only stabilize the particles, but also, more 
importantly, it encapsulated siRNA inside particles without dependence on the 
electrostatic interaction. This feature minimized the unspecific interaction between 
neutral crosslinked particles and other components in the extracellular environment. Yet 
the crosslinking reaction also increased the complexity of the system. In the ternary 
blends of dendrimer, siRNA, and glutaraldehyde, PAMAM-HYD or GPHs would 
simultaneously bind with siRNA and react with glutaraldehyde. Crosslinking could occur 
within the complexes formed from siRNA and dendrimer materials, termed as 
intra-particle crosslinking. Meanwhile, the initially crosslinked complexes could further 




inter-particle crosslinking would lead to the formation of larger particles. Consequently, 
the average particle size in the system resulted from the dynamic equilibrium between the 
intra-particle crosslinking and inter-particle crosslinking. The inter-particle crosslinking 
caused the increased average sizes of PAMAM-HYD systems with the increasing 
glutaraldehyde concentrations at the beginning. However, when the amount of 
glutaraldehyde reached a certain threshold capable of saturating the surface hydrazide 
groups, inter-particle crosslinking would be prevented, allowing the formation of small 
particles. On the other hand, decorating the dendrimer surface with GalNAc likely 
increased the surface hydrophilicity and reduced the accessibility of surface hydrazide 
groups in dendrimers, to some extent preventing the inter-particle assembly after the 
dendrimer-siRNA complexes were initially crosslinked. In this case, the higher 
modification levels of GalNAc resulted in smaller size of the crosslinked particles. Thus, 
the sizes of crosslinked particles can be modulated both by the crosslinker concentration 
and surface modification. 
Controlled release of siRNA is likely to be realized in the crosslinked system. One 
concern for the cationic delivery vehicles is that the electrostatic forces may restrict the 
gene cargoes from leaving the delivery system into cytoplasm, and in fact studies already 
reported that too condensed particles are not efficient for gene delivery [157-161]. In the 
neutral crosslinked system, the siRNA release could occur upon the breakage of the 
hydrazone crosslinking bonds in the acidic endosomal environment, when free 
glutaraldehyde was not present in excess to drive the reaction toward bond formation. 
Theoretically, the hydrazone bonds would break in endosomes, and then siRNA would 




would induce the ―proton sponge‖ effect and break the endosomes. Subsequently, siRNA 
could be released into the cytoplasm.  
Saccharide ligands are multi-tasking in the crosslinked system. They provide 
biocompatibility as well as the controllability on the siRNA loading efficiency and 
particle size, and also support cell targeting and cell internalization. The fluorescence 
images demonstrated that GalNAc plays a pivotal role in mediating the cellular uptake of 
neutral dendrimers and crosslinked particles. The multivalent effects normally exerted by 
glycodendrimers were likely to further magnify the interaction between GalNAc and its 





CHAPTER 4  
DOWN-REGULATION OF AT1R IN CARDIAC TISSUE BY 




The short peptide hormone Ang II is the key player in Renin-Angiotensin- 
Aldosterone System (RAAS), which would be activated upon ischemic injuries. 4 
membrane receptors have been identified for Ang II. Most well-known adverse effects of 
Ang II are mediated by the Ang II type 1 receptor (AT1R), the activation of which results 
in worsened cardiac functions after injury [66, 67, 162]. In comparison, another important 
receptor, the type 2 receptor (AT2R), is generally considered as a protective receptor, 
leading to improved function recoveries [78, 79, 163]. Consequently, AT1R has become 
a common target for the management of cardiac diseases. The suppression of AT1R 
activity can reduce the deleterious effects from Ang II, and meanwhile Ang II can mostly 
bind AT2R, bringing more beneficial effects upon AT2R activation [164]. Evidence from 
laboratories and clinical studies showed that Angiotensin receptor blockers (ARBs) are 
effective to restore blood pressure, prevent fibrosis, and improve cardiac function [71-73, 
75, 76].  
Despite the obtained positive results so far, some studies demonstrated that the 
AT1R suppression at the gene expression level holds more advantages to AT1R 




Ang II levels to increase in plasma, which may further activate the whole RAAS, but the 
delivery of antisense oligonucleotides against AT1R didn’t bring this problem [70]. 
Possibly the simple blockade interrupts the feedback loop in RAAS, leading to 
deregulation of other components in the system. In Voros et al.’s study, the 
overexpression of AT2R significantly reduced the fibrosis degree post-MI in an 
AT1R-knockout animal model, but such improvement was not observed in the animals 
treated with AT1R blockers [165]. Apparently, the silencing of AT1R at the gene 
expression level differs from the direct blockade of the AT1R protein. In addition, an 
argument about whether the AT1R blockers may increase the risks of MI and cancer is 
undergoing, which brings more concerns for the traditional therapy. Such situation puts 
RNAi therapeutics into an important position, as it can selectively control gene 
expression, and siRNA molecules are the potent initiators to trigger gene silencing.  
One crucial challenge for applying RNAi therapeutics to treat CVDs is the 
development of siRNA delivery systems for cardiac tissue, because the non-phagocytic 
nature of cardiomyocytes raises the barrier for the delivery of small RNA molecules. Bull 
and his colleagues did a series of studies using a synthetic polymer carrier to deliver 
siRNA in a cardiomyoblast cell line, in the form of peptide-conjugated polymers or the 
peptide-conjugated siRNAs, but no further in vivo efficiency was reported so far [93, 95, 
101], possibly due to the efficacy issue. Lau et al. used a siRNA-albumin conjugate to 
silence cardiac genes in vivo at a siRNA dose of 1-5 mg/kg. Though a 40% silencing 
effect was obtained, the usage of a significantly higher dose than those in other studies 
indicated that the actual performance was not very competitive [166]. Due to the poor 




In our previous studies, we explored the polymeric materials, the dendrimeric 
materials, and the CPP ligands, and all of them own unique advantages in siRNA delivery. 
In this part, we want to combine the strengths of the three components above. A ―tadpole‖ 
shaped dendrimeric material was developed in this part, composed of a cationic dendron 
head, a PEG polymer crosslinker, and a CPP tail, and this design allows a strong affinity 
with siRNA, reduced surface charge density, and enhanced cell membrane penetration. 
Three tadpole dendrimers were tested and compared in vitro first, including one without 
CPP modification and two with CPP conjugations. The vehicle worked best was further 
studied in a rat ischemia-reperfusion (IR) model to assess its performance in vivo, using 
AT1R as the gene target. 
4.2 Results 
Synthesis of tadpole dendrimeric materials 
Figure 4.1 showed the design of the tadpole dendrimeric materials. They have a 
dendron head, a PEG crosslinker in the middle, and a CPP tail. The fan-shape dendron 
moiety was derived from the reduced cystamine core G4.0 PAMAM, presenting 32 
positive charges on the surface, which provide high-density siRNA-binding sites. The 
hydrophilic and neutral PEG segment would not involve in the charge interaction, 
possibly presenting on the outer layer of siRNA-loaded particles, which could partially 
shield the cationic charges on the particles to reduce the potential toxicity. At the same 
time, the flexibility of PEG could also minimize the steric hindrance between the peptide 
tails when interact with cell membranes. CPPs were introduced into the tadpole 




cleavable disulfide bonds to endow the materials with degradability and the siRNA 
release mechanism in cytoplasm.  
The conjugation of PEG and CPP to the dendron moiety was confirmed by the 
H
1
-NMR spectra (Figure 4.1b). The high peak in the range of 3.7-3.8 ppm belongs to the 
PEG segment (-OCH2CH2-), the relatively wide peak in the range of 2.4-2.6 ppm belongs 
to PAMAM (–NCH2CH2CO–), and the two adjacent peaks in the range of 1.5-1.8 ppm 
belong to the arginine residues (–HCCH2CH2CH2NH–) in the peptides. Qualitative 
calculations based on the peak area of PAMAM, PEG, and arginine showed the 
successful conjugation of PEG to the reduced end of PAMAM, and averagely 81.8% and 




Figure 4.1 Scheme of tadpole dendrimers (a) and H
1
-NMR analysis (b). NMR 
results showed that the modification rates of R9 and TAT were 81.8% and 80.0% 
in f-PAMAM-PEG-R9 and f-PAMAM-PEG-TAT tadpole dendrimers, 








Preparation of siRNA-loaded particles 
siRNA loading capacity of the tadpole dendrimers was evaluated by the gel 
retardation assay. Clearly the siRNA bands became fainter in the gel with the increasing 
N/P ratios, meaning siRNA gradually formed particles based on the electrostatic 
interaction with the increasing amount of dendrimeric materials. According to the gel 
pictures, the minimal N/P ratios required to load all siRNA in each system were 10, 60, 
60, and 40 for G4.0 PAMAM, f-PAMAM-PEG, f-PAMAM-PEG-TAT, and 





Dynamic light scattering (DLS) was used to determine the size of siRNA-loaded 
particles formed by different tadpole dendrimers at the minimal required N/P ratios. The 
particles made from PAMAM G4.0, f-PAMAM-PEG, f-PAMAM-PEG-TAT, and 
f-PAMAM-PEG-R9 had diameters of 247 ± 76 nm, 178 ± 13 nm, 302 ± 20 nm, and 143 
Figure 4.2 Gel retardation assay of G4.0 PAMAM and tadpole dendrimers. 
siRNA bands became fainter when the N/P ratios were raised higher. The minimal 
N/P ratios needed to load siRNA completely were 10, 60, 60, and 40 for G4.0 






± 29 nm, respectively (Figure 4.3 and Table 4.1) at N/P ratios of 10, 60, 60 and 40. And 
the corresponding zeta-potentials of these particles were measured as 29.9 ± 4.1 mV, 10.6 




Table 4.1 Size and zeta-potential of siRNA-loaded particles
1
 
Tadpole dendrimer Diameter (nm) Zeta-potential (mV) 
PAMAM G4.0 247 ± 76 29.9 ± 4.09 
f-PAMAM-PEG 178 ± 14 10.6 ± 4.35 
f-PAMAM-PEG-TAT 302 ± 20 15.4 ± 4.01 
f-PAMAM-PEG-R9 143 ± 29 3.51 ± 0.6 
1
Adapted with permission from Liu (2013) [96]. Copyright (2013) Elsevier. 
 
Though numbers of studies have reported the toxicity of cationic PAMAM [33], 
no adverse effect from tadpole dendrimers in the metabolic activity was detected in 
Figure 4.3 Size distribution of siRNA-loaded tadpole dendrimer particles. The 
f-PAMAM-PEG-R9 formed relatively small particles with siRNA, while 
f-PAMAM-PEG-TAT formed relatively large particles. Adapted with permission 






primary CMs by MTT assay (Figure 4.4), and all particle-treated groups had cell 





siRNA transfection in isolated cardiomyocytes 
In our preliminary test, both TAT- and R9-conjugated tadpole dendrimers showed 
the capability of delivering FITC-siRNA into cardiomyoblast cell line H9C2, as strong 
fluorescent signals were observed inside cells (Figure 4.5). To determine the transfection 
efficiency of tadpole dendrimers in primary cardiac cells, we applied the siAT1R-loaded 
dendrimer particles in neonatal CMs and used qPCR to detect the AT1R expression at the 
mRNA level. At the siRNA concentration of 50 nM, AT1R expression didn’t changed 
significantly upon the treatment of siRNA-loaded particles made from G4.0 PAMAM, 
f-PAMAM-PEG and f-PAMAM-PEG-TAT compared to the cells treated with the three 
Figure 4.4 Cytotoxicity of siRNA-loaded tadpole dendrimer particles in 
primary neonatal CMs. The MTT assay showed that cells treated with particles 
made from f-PAMAM-PEG or f-PAMAM-PEG-R9 had cell viabilities no less than 
90%, and cells treated with particles made from f-PAMAM-TAT had cell 







empty dendrimeric materials (104.3 ± 27.8%, 120.8 ± 24.9% and 96.7 ± 9.6%, 
respectively), but siRNA-loaded particles made by f-PAMAM-PEG-R9 induced a 
silencing effect greater than 60% (36.7 ± 9.9%, P<0.01) (Figure 4.6). Since 
f-PAMAM-PEG-R9 exhibited the strongest in vitro performance with the highest siRNA 
loading efficiency, the smallest particle size, and the lowest surface positive potential, it 




Figure 4.5 Cellular internalization of FITC-siRNA loaded tadpole dendrimer 
particles in cardiomyoblast H9C2 cells. Cells treated with siRNA-loaded 
particles made from both f-PAMAM-PEG-TAT (a) or f-PAMAM-PEG-R9 (b) 
showed positive fluorescent signals in the images. Adapted with permission from 









siRNA delivery in vivo 
To determine the siRNA delivery efficiency of f-PAMAM-PEG-R9 dendrimer 
and the therapeutic potential of siRNA delivery in cardiovascular diseases, we conducted 
animal experiments in a rat IR model. The IR injury was made by surgeries in adult male 
rats, and the operated animals were randomly divided into three groups that either 
received the injection of saline alone (IR), or empty tadpole dendrimers (IR+ dendrimer), 
or siAT1R-loaded particles (IR+ dendrimer/ siRNA) (n>6 for each group, N=36 total). A 
group of animals that only went through chest opening without artery ligation was used 
as the sham group for comparison. On the third day after the injection, gene expression in 
Figure 4.6 AT1R expression upon the treatment of siRNA-loaded tadpole 
dendrimer particles in primary neonatal CMs. According to the qPCR result, 
only particles made from f-PAMAM-PEG-R9 induced a significant 
down-regulation of AT1R in vitro, with a silencing effect of 63.3%. The results 
were normalized to 18S expression (fold change) reported as mean ± SEM. n=3-4, 





left ventricle tissue was determined by qPCR. AT1R expression increased significantly 
by 1.92 ± 0.26-fold and 2.01 ± 0.37-fold (P< 0.05) at mRNA levels in IR group and IR+ 
dendrimer group, respectively, compared to the sham group. In contrast, the AT1R 
expression in the IR+ dendrimer/siRNA group maintained a similar level (0.94 ± 0.21 
fold) as sham animals, significantly lower than that in IR injured animals (P<0.05) 
(Figure 4.7a).  
Except the direct target AT1R, other relative genes in the MI development were 
also in the scope of detection. The expression of AT2R, the other important receptor of 
Ang II, slightly decreased in the IR group (0.74 ± 0.20 fold) and IR+ dendrimer group 
(0.69 ± 0.20 fold) compared to the sham group, while in comparison, the AT2R level 
increased in the IR+ dendrimer/ siRNA group by 2.14 ± 0.86-fold, but none of these had 
statistic significances yet at the 3-day time point (Figure 4.7b). The expression of another 
relative gene Col-1, which associates with fibrosis formation, was also determined by 
qPCR. The expression of Col-1 increased by more than 5 folds after the IR injury, while 
in the siRNA delivery group the Col-1 expression decreased to 2.7 ± 0.85-fold of the 







In vivo cardiac function 
To determine whether the siRNA delivery against AT1R by the tadpole dendrimer 
preserved cardiac functions after the ischemic injury, cardiac functions were evaluated by 
echocardiography and Pressure-Volume (PV) cardiac hemodynamics (n>6 for each group, 
Figure 4.7 Expression of AT1R (a), AT2R (b), and Col-1 (c) in the left 
ventricle tissue upon the delivery of siRNA loaded tadpole dendrimer 
particles. At the 3 day after injection, the expression levels of AT1R, AT2R, and 
Col-1 in the IR+ dendrimer/siRNA group were 0.94 ± 0.21 fold, 2.14 ± 0.86-fold, 
and 2.7 ± 0.85-fold of that of the sham group. Results were normalized to the 18S 
expression and reported as mean ± SEM. n>6, N=36, *P<0.05. One-way ANOVA 
followed by the Tukey post-test. Adapted with permission from Liu (2013) [96]. 








N=26 total). Ejection fraction (EF) stands for the percentage of blood pumped out from 
ventricles in each heart cycle, and rats in the sham group had an average EF value of 74.3 
± 2.7% that was significantly lower in the IR group (56.3 ± 2.4%, P<0.005) and IR+ 
dendrimer group (62.0 ± 2.4%, P<0.01); however, a significant improvement of EF was 
observed in the IR+ dendrimer/siRNA group (71.9 ± 1.9%, P<0.005 vs. IR, P< 0.05 vs. 




The end-systolic volume (ESV) indicates the heart contractility. In IR group, ESV 
increased significantly to 1.68-fold (127.8 ± 6.4 μl, P<0.01) of that in the sham group 
(76.0 ± 6.4 μl), implying a loss of ventricular contractility and increase in elasticity. The 
unloaded empty dendrimers didn’t cause significant changes (125.9 ± 14.5 μl), but the 
Figure 4.8 Ejection fraction (EF) of different treatment groups at the 3 day 
after injection. While the EF values of IR and IR + dendrimer groups significantly 
decreased after the IR injury, the delivery of siAT1R increased the EF value to 
71.9 ± 1.9%. Values are mean±SEM. n>6, N=26, *P<0.01, ***P<0.005. 
One-way ANOVA followed by the Tukey post-test. Adapted with permission from 






treatment of the siRNA-loaded dendrimer particles led to a significant improvement with 
a lowered ESV of 84.6 ± 8.6 μl (P< 0.01 vs. IR, P< 0.05 vs. IR+ dendrimer) (Figure 4.9a). 
Unlike ESV, no significant difference in the end-diastolic volume (EDV) was observed 
among different treatment groups, and the EDV values of sham, IR, IR+ dendrimer, and 
IR+ dendrimer/siRNA groups were 222.1 ± 18.1 μl, and 250.2 ± 12.8 μl, 263.7 ± 10.2 μl, 




At the third day following injury, infarct size was measured in different treatment 
groups using the TTC staining method, and a typical picture would show three color 
sections: the dark blue area presented the viable tissue, the red presented the area at risk, 
Figure 4.9 End-systolic volume (ESV) (a) and end-diastolic volume (EDV) (b) 
of different treatment groups. In the acute phase of ischemic injury, the ESV 
value significantly increased after IR injury, and the delivery of siAT1R-loaded 
tadpole dendrimer particles decreased the ESV to 84.6 ± 8.6 μl. No significant 
difference among treatment groups was observed for EDV at the 3 day after the 
surgery. Values are mean ± SEM. n>4, N=21, *P<0.05, **P<0.01. One-way 
ANOVA followed by the Tukey post-test. Adapted with permission from Liu 







and the white presented the dead tissue. The pictures of heart slides showed that in the 
dendrimer/siRNA group the white area was much smaller than that in the IR group 
(Figure 4.10a). To quantitative compare the occupation of damaged tissue among groups, 
the index of infarct size was calculated as infarct area/area-at-risk to avoid the influence 
from variations in risk areas. By dividing the white area by the sum of white and red 
areas, the infarct size of the IR group was calculated as 47.8 ± 4.8%. While there was no 
statistically significant decrease in the IR+ dendrimer group (37.5 ± 2.7%), the treatment 
of siAT1R-loaded dendrimer particles significantly reduced the infarct size to 18.4 ± 3.1% 




Optimization of the tadpole dendrimers 
To further optimize the tadpole dendrimeric materials, the PEG segment was 
Figure 4.10 Infarct size of different treatment groups. Stained heart slides 
showed three colors, with the white section indicative of infracted tissue. 
Quantitative measurements from Image J showed that the treatment of 
siRNA-loaded tadpole dendrimer particles reduced the infarct size from 47.8 ± 
4.8% to 18.4 ± 3.1%. Values are mean ± SEM. n=5, **P<0.01, ***P<0.005. 
One-way ANOVA followed by the Tukey post-test. Adapted with permission from 







shortened from 2 KDa to 1 KDa, and new f-PAMAM-PEG and f-PAMAM-PEG-R9 were 
produced, termed as f-PAMAM-PEG1000 and f-PAMAM-PEG1000-R9. Both new tadpole 
dendrimers showed increased siRNA loading efficiency in the gel retardation assay, with 
the minimal required N/P ratios reduced to 20 and 10 for f-PAMAM-PEG1000 and 
f-PAMAM-PEG1000-R9, respectively (Figure 4.11a). siRNA-loaded particles formed at 
the minimal N/P ratios had diameters ranged from 100 nm to 300 nm, which were still 




Dendrimeric materials are potent candidates for siRNA delivery as described in 
Chapter 3. Particularly, PAMAM has been widely employed due to its high charge 
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Figure 4.11 Characteristics of the optimized tadpole dendrimers. Gel 
retardation assay examined the siRNA loading efficiency of tadpole dendrimers 
after changing the PEG segment. The minimal N/P ratios needed to load siRNA 
completed reduced to 20 and 10 for f-PAMAM-PEG and f-PAMAM-R9, 
respectively. siRNA-loaded particles made from the new tadpole dendrimers had 





and in vivo were reported [167, 168]. Due to the previously good performance, we 
wanted to exploit the potential of PAMAM to construct a potent delivery system in the 
non-phagocytic CMs. The cell binding and internalization of a neutral 
saccharide-modified dendrimer and a cationic dendrimer were compared in 
cardiomyoblasts first in our primary test. GlcNAc was chosen as the saccharide ligand for 
CMs to be modified on PAMAM-HYD, since GlcNAc was reported promising in 
targeting CMs [98, 99]. However, the combination of GlcNAc ligands and the 
multivalent interaction still could not compete with the cationic PAMAM. The flow 
cytometry analysis showed that the amount of G5.0 PAMAM bond and uptake by 
cardiomyoblasts was much more than that of GlcNAc-PAMAM-HYD. In this case, the 
cationic dendrimer was chosen to establish siRNA delivery system for cardiac tissue. 
To improve the performance of cationic dendrimers and meanwhile avoid 
potential problems, we used a PAMAM moiety as the head of the tadpole dendrimers to 
load siRNA with a strong affinity, and the CPP tail served to enhance the internalization 
of siRNA-loaded particles in CMs. To reduce the potential toxicity from the dendron 
moiety, a PEG segment was introduced into the structure [23-26] to shield the positive 
charges. The three parts of the tadpole dendrimers are responsible for independent tasks 
and also cooperate with each other to function as a whole. 
PEG segment is an important adjuster in the tadpole dendrimers. With the PEG 
modification, the zeta-potential of f-PAMAM-PEG particles decreased nearly 3 folds 
compared to the particles formed by PAMAM G4.0. Similar decreases in zeta-potentials 
were also observed in the f-PAMAM-PEG-R9 and f-PAMAM-PEG-TAT dendrimer 




reducing the exposure of cationic charges. The significantly lowered zeta-potential of R9 
dendrimer particles compared to the other tadpole dendrimers was probably due to the 
smaller N/P ratio required by this material (40 for f-PAMAM-PEG-R9 vs. 60 for 
f-PAMAM-PEG or f-PAMAM-PEG-TAT). Besides reducing the exposure of positive 
charges, the PEG segment also affected the siRNA loading efficiency. Without the PEG 
conjugation, cationic G4.0 PAMAM only needs an N/P ratio of 5 to load siRNA 
completely, but after conjugation of PEG2000 this value increased to 60 for 
f-PAMAM-PEG. It’s likely that the PEG interrupted the interaction between PAMAM 
moiety and siRNA, and this hypothesis was confirmed by the new f-PAMAM1000-PEG, 
as the shorter PEG significantly reduced the minimal required N/P ratio to 20. The same 
trend also occurred on f-PAMAM2000-R9 and f-PAMAM1000-R9. The appropriate size of 
PEG could be critical for optimizing the material’s property.  
In the transfection experiment in vitro, PAMAM G4.0 and f-PAMAM-PEG 
loaded with siAT1R failed to reduce the AT1R expression, implying that the charge 
interaction alone is not sufficient to translocate the particles into CMs. CPPs are the top 
choices to enhance the cell internalization, and the two most commonly used CPPs, R9 
and TAT, have been reported to enhance the delivery efficiency in cardiac cells and 
myocardium in literature [95, 103, 104]. In this part, the R9-conjugated tadpole 
dendrimer caused effective siRNA delivery, but the TAT-conjugated dendrimer failed to 
do the same. R9 is a short peptide composed of pure arginine residues, while TAT is a 
longer peptide with two types of basic amino acids, arginine and lysine, and other 
hydrophobic residues in the sequence. The difference in the transfection efficiency of the 




phenylalanine residues creating a secondary structure different than that of R9, or the 
higher number of arginine residues in R9 meets the preference of CMs. In addition, the 
difference in particle sizes between the two tadpole dendrimers may also affect the 
transfection efficiency since smaller particles are generally easier to be internalized.  
The treatment of siAT1R-loaded dendrimer particles regulated not only the 
expression of the direct target AT1R but also other relative genes. AT2R is another major 
receptor that Ang II binds to and exerts mostly beneficial effects. Some studies showed 
the treatment of AT1R blockers caused increased AT2R expression, while in other 
studies AT2R wasn’t affected [169-171], which was possibly determined together by the 
type of blockers, the type of injury models, and the time of detection. Yang et al. used an 
antisense RNA to silence AT1R in an IR model in rat hearts, leading to a decrease in 
AT2R level [70], potentially mitigating some of the beneficial effects [96]. In our results, 
the knock-down of AT1R at the mRNA level tended to induce AT2R overexpression 
compared to the sham group, but not to a significant degree. Since the overexpression of 
AT2R was reported to be beneficial to cardiac functions in the rat IR model, the RNAi 
therapy targeting AT1R could gain a double-win from the modulation of AT1R and 
AT2R. Col-1 is another important gene for cardiac functions, which responses to the 
fibrosis formation in the infarct area. The synthesis of Col-1 increased upon Ang II 
activation [172]. In the present study, IR injury increased the Col-1 level, and siAT1R 
delivery demonstrated a trend at reducing this. It’s possible the change in this chronic 
fibrosis marker will become significant in a long time term.  
siRNA delivery against AT1R in vivo enhanced CM survival as evidenced by the 




curing effect of the empty dendrimer was showed in the experiment, the reduced infarct 
size was a direct result of the AT1R silencing. This is consistent with previous studies 
demonstrating that Ang II caused cell death in CMs [173, 174], as well as studies 
demonstrating ARBs capable of reducing infarct size [169, 175, 176]. The improvement 
in the cell viability further brought the improvements of cardiac function. One 
representative parameter of cardiac function is the EF. A normal rat has an EF around 
60%-80%, and IR injury significantly decreased this value down to 50%. siAT1R 
delivery by R9 tadpole dendrimer recovered the EF value to the same level of the sham 
group, indicating the recovery of the heart ability to pump blood. ESV is the volume of 
ventricles at the end of heart contraction, and a relatively small ESV means a relatively 
strong capability of contracting. Our result showed that the siAT1R delivery reversed the 
increasing tendency of ESV after IR injury, implying the preservation of heart 
contractility. Correspondingly, EDV is the ventricle volume at the end of heart relaxation, 
but no significant difference of EDV was observed between different treatment groups at 
the early time point of 3 day. In addition, the CPP ligand R9 is not specific to CMs but 
generally enhances cell internalization, so the silence of AT1R possibly took place in 
several types of cells that express AT1R, such as cardiomyocytes, fibroblasts, endothelia 
cells, and inflammatory cells. The down-regulation of AT1R in multiple types of cells 




CHAPTER 5  
SUMMARY AND FUTURE DIRECTIONS 
 
5.1 Peptide polymers in siRNA delivery 
Chapter 2 described the synthesis and usage of a degradable arginine peptide 
polymer in siRNA delivery in vitro and the comparison with an oligo arginine peptide 
and an undegradable peptide polymer. This part verified three basic hypotheses in 
polymer materials. First, the polymerization strategy of oligo peptides is effective in 
enhancing the interaction between siRNA and peptides and further enhancing the stability 
of siRNA- loaded particles. Second, the degradable design of peptide polymers is able to 
reduce the cytotoxicity from cationic charges. Third, the conjugation of functional 
ligands benefits the delivery efficiency of delivery systems. In fact, several studies have 
synthesized CPP polymers via the linkage of disulfide bonds for gene delivery, and 
similar advantages of polymeric structures compared to their monomers were found, but 
the conjugation of functional ligands to CPP polymers was not reported before. 
Although CPP polymers gained improved performance compared to CPP 
monomers, the simple polymerization of CPPs could hardly create ideal delivery systems. 
The highest gene silencing effect detected in our study was about 50% in serum-free 
medium, which was much lower than the 92% from the positive control lipofectamine. 
Undoubtedly, CPPs are good at penetrating cell membranes, but they lack the capability 
of endosome escape. Therefore the retention in endosomes may be the reason for the low 




performance. When the dPOA/siRNA particles and RGD-g-dPOA/siRNA particles were 
used in serum-containing medium, the gene silencing effects disappeared, indicating that 
the particles formed from peptide polymers were not stable against serum proteins. As a 
conclusion, CPPs alone are not the ideal candidates to become the hardcore of a delivery 
system, and instead the collaboration between CPPs and other components would become 
the future direction for the utilization of CPPs. Several studies decorated CPPs and other 
types of targeting ligands together on delivery vehicles, and synergetic effects in 
enhancing cell internalization were observed compared to the usage of the ligands 
separately[93, 95]. CPPs would perform as good supporters to improve the delivery 
efficiency of gene delivery systems, especially to the difficult targets.   
How to use ligands wisely needs to be considered in the future. Not only in my 
results but also in literatures, the significant improvement of ligand-modified systems 
always showed at relatively high N/P ratios [95, 101], maybe when the ligand density 
meets a bottom limit. To increase the density of ligands, dendrimers offer a promising 
solution. The rich peripherals on the dendrimer surface provide the sites for ligand 
modification, and the ligand density can be regulated in the chemical reaction. Saccharide 
ligands on dendrimers have been verified to have a special multivalent interaction with 
their receptors, which magnifies the interaction by more than 100 folds [177-179]. Unlike 
saccharide ligands, peptide ligands on dendrimers don’t have such magnitudes of 
elevation, but such pattern also showed benefits to cell binding, cell recognizing, and cell 
internalization [39, 180-182]. Gray et al. conjugated the multivalent RGD or R9 peptides 




efficiency of microRNA to HUVEC cells compared to the unmodified materials [183], 
showing the benefits from multifunctional ligands. 
Degradability will become a necessary character of cationic polymers in the 
future. The difference between R9 and PLR demonstrated that the high-density positive 
charges were the origin of cytotoxicity, and the degradable design addressed the issue in 
our results. In addition, the degradation of carriers allows the release of siRNA from the 
delivery vehicles to initiate RNAi process; otherwise siRNA can’t perform its function. 
Thus the degradability is critical for both safety and function of cationic delivery systems.       
 5.2 Neutral crosslinked dendrimeric systems 
The neutral crosslinked system brings a new concept in constructing gene 
delivery systems, by using the combination of the buffering amines, a crosslinking 
method, and surface ligands to replace the role of primary amines in cationic materials. 
The established delivery vehicles are superior to traditional cationic delivery vehicles at 
five aspects. First, the replacement of primary amines significantly reduces the toxicity 
compared to the original cationic materials. The distinct performance between G5.0 
PAMAM and PAMAM-HYD in MTS assay provided solid evidence for this point. 
Second, the neutrality of the crosslinked particles minimizes the non-specific interaction 
with extracellular components, reducing the risk of unexpected particle dissociation. It is 
very common for cationic particles to interact with anionic proteins in serum or ECM, 
which is one major reason attributed to their instability, but the neutral crosslinked 
particles avoid such drawback. Third, the crosslinking bonds hold the neutral particles 
stable from deformation and dissociation, further prolonging the effective time window 




secondary self-assembling between each other over time, and the particle size exhibited a 
growing tendency after formulation [156]. Such deformation of particles caused the 
decreased transfection efficiency in cells, but the transfection efficiency could be 
preserved when the particles were crosslinked [156]. In our study, the crosslinking 
strategy benefited the neutral particles in the same way. Forth, the neutral crosslinked 
system is tunable regarding the siRNA loading efficiency, the particle size, and the 
targeting capability. The final transfection efficiency is a combinational result from these 
factors, and each of them can be finely adjusted by the crosslinker concentration and the 
surface ligand density. In contrast, the charge-interaction based particles are generally 
formed dependent on random self-assemblies without controllability. Fifth, the neutral 
crosslinked particles have the potential to release siRNA into cytoplasm when the 
cleavage of crosslinking bonds is triggered under a specific environment, but the timing 
of siRNA release from cationic delivery vehicles is vague and uncontrolled. To sum up, 
the neutral crosslinked dendrimeric system provides safety, stability, and controllability 
for siRNA delivery, which can be considered as a breakthrough in this area. 
The choice of ligands is critical for the efficiency of the neutral crosslinked 
system. Due to the absence of charge interactions with cell membranes, the cell 
internalization of neutral particles basically depends on the surface ligands. The suitable 
ligands promote the cell binding, cell recognizing, and cell internalization, and with the 
multivalent effects brought by the dendrimeric structure such enhancement could be 
magnified. Yet on the other hand, inappropriate ligands with multivalent effects may 




delivery vehicles. Accordingly, if the neutral crosslinked particles need to be applied to 
other types of cells, a potent ligand needs to be identified before the particle formulation. 
The concept of the neutral crosslinked system is not restricted to the PAMAM 
dendrimer, and in fact any dendrimer, polymer, or other types of materials containing 
buffering amines in their structures can be considered for this idea. For instance, PEI, 
which is very famous of its high transfection efficiency as well as the high cytotoxicity, is 
being kept away from human studies due to the safety concern. If the PEI is transformed 
into a neutral material that preserves the outstanding delivery capacity and meanwhile 
alleviates the toxicity, the hurdle that prevents PEI from clinical applications could be 
removed. Considering the low cost of PEI compared to the PAMAM dendrimer, the 
neutral delivery system based on PEI is actually more promising to be finally translated 
into manufacture and medical practices. 
The current rational of the neutral crosslinked system need to be further optimized. 
Right now the formulation procedure of the crosslinked particles is relatively complicated, 
containing multiple steps. The main reason is actually the concern for the toxicity of 
glutaraldehyde, so blocking with small molecules and dialysis are used in the protocol to 
remove all unreacted glutaraldehyde. To simplify the procedure, a biocompatible 
crosslinker should be introduced into the system, and the peripheral of the neutral 
dendrimer should be changed to a corresponding group that can react with the new 
crosslinker. To make sure the whole system preserves the degradability and the siRNA 
controlled-release mechanism, the crosslinking bond is better to be reversible at 
intracellular environments, such as the disulfide bond, acetal linkage, ester linkage, and 




main body of the material or the crosslinker can also serve to release siRNA under 
specific conditions. With a simplified formulation procedure, the translation of the 
neutral crosslinked delivery system into clinical practices could become expectable. 
 
5.3 Dendrimeric delivery systems in cardiac tissue 
The R9-conjugated tadpole dendrimer developed in Chapter 4 paves a way for 
using RNAi therapeutics in treating cardiovascular diseases. The safety of the materials 
was confirmed by the MTT assay in primary CMs in vitro, and the delivery efficiency 
was verified by the regulated gene expression and the improved cardiac functions. Thus 
the tadpole dendrimers are promising non-viral gene delivery systems in cardiac tissue, 
and they are not restricted for siRNA but maybe also suitable for other small nucleic acid 
molecules, such as microRNA. Moreover, an increasing number of cardiac-specific 
microRNAs that can enhance cardiac regeneration [19-21] have been discovered recently. 
To fully exploit the usage of the tadpole dendrimers, new targets and new therapeutic 
molecules could be applied. 
The behavior of siRNA after delivery is worthy being further studied. In the 
current tadpole dendrimers, CPPs are used as the functional ligands, which enhance the 
cell internalization of carried cargoes. Although we expected the cell uptake of 
siRNA-loaded particles in CMs could be improved by the CPP conjugation, it was 
possible that other types of cells also endocytosized the delivery vehicles and had 
down-regulated AT1R expression. For instance, the R9 was reported to promote the 
microRNA delivery to HUVECs based on a dendrimeric material [183]. In this case, the 




cells that poured in after injury happened. The remaining question is whether the 
improved cardiac functions resulted solely from the AT1R down-regulation in CMs or 
not. Telling apart the contribution made from different types of cells may give us a hint if 
the specific targeting to one type of cells is highly required or the general gene regulation 
in cardiac tissue also works well. Undoubtedly, the situation may be different depending 
on the target gene, but a small study on the distribution of delivered siRNA in cardiac 
tissue would be helpful in the future.  
The design of tadpole dendrimers allows the chance for the systemic and targeted 
delivery by replacing the CPP ligand with a targeting ligand. In particular for cardiac 
tissue, the collaboration between CPPs and targeting ligands is encouraged, as the CPP 
played a crucial role to enhance the cell uptake of the delivery vehicles in CMs in our 
study. In fact, Bull et al. compared TAT and a CM-specific ligand PCM in their 
polymeric system and tried the combination of the two ligands. According to their results, 
TAT-conjugated vehicles had higher transfection efficiency in vitro, while 
PCM-conjugated vehicles showed stronger capability of specifically targeting to CMs 
other than fibroblasts. The mixture of the two ligands actually exhibited synergetic 
effects with better performance than the two single ligands. Therefore, the cooperation 
between CPPs and targeting ligands could be a potent tool for systemic delivery, and 
such strategy could be tried on the tadpole dendrimers in the future. 
The incorporation of gene delivery systems into other biomedical engineering 
methods may also be a future direction. Currently, the majority of gene delivery systems 
focus on the transient gene regulation, but many diseases need a regulation in a long time 




window from 3 day to weeks post-MI. To suppress the AT1R activation during this time 
period, traditional pharmacological AT1R blockers can be orally administrated every day, 
easy and convenient; however, as to siRNA delivery, current techniques can hardly fully 
cover this time period without repeated injections, which would bring more painful 
experience if translated to patients. Therefore, the controlled release of siRNA-loaded 
particles instead of siRNA itself will become an upcoming issue. One possible idea is to 
incorporate siRNA-loaded delivery vehicles into hydrogels, such as alginate hydrogel 
used by Cohen’s group to repair damage tissue in hearts [184]. siRNA-loaded particles 
could diffuse from the hydrogel over time, which wouldn’t affect the release of 
gel-loaded growth factors into the environment if there’s any. In this case, such system 
could combine the healing function from hydrogels and the gene regulation function from 
the delivery vehicles, and meantime preserve the protein delivery function of the gel. 
Similarly, tissue-engineering scaffold attached with siRNA-loaded particles may also be 
considered for the further development. 
5.4 Concluding remark 
Three innovations were demonstrated in the dissertation. 
1. The dissertation described the investigation of the CPP polymers to illustrate 
the strengths of polymeric materials and the contribution of functional ligands to the 
transfection efficiency of CPP polymers. 
2. The dissertation described the development of the neutral crosslinked 
dendrimeric system, which brings a new concept for the development of gene delivery 
systems. 




modulating gene expression in cardiac tissue and demonstrated the usage of RNAi 
therapeutics in a cardiac IR model, which promotes the development of gene therapy in 
the cardiovascular disease management.  
This dissertation developed effective polymeric and dendrimeric siRNA delivery 
systems with reduced toxicity as well as enhanced stability and targeting efficiency, and 
they are paving ways for novel non-viral siRNA delivery systems for gene therapy. With 
the rapid progress in the area of gene delivery, gene therapy will become a powerful 
weapon for the management of critical diseases and personalized therapy to improve 





APPENDIX A  
MATERIALS AND METHODS 
 
Synthesis of degradable poly(oligo-arginine) (dPOA) polymers 
dPOA was produced by an oxidative polycondensation method in a mild oxidative 
environment. Briefly, Ac-CRRRRRRRRRC-NH2 (CR9C) (or 
Ac-CRRRRRRRRRKC-NH2 (CR9KC)) and Ac-CRRRRRRRRR-NH2 (CR9) were mixed 
as a molar ratio of 3:1 in 20% DMSO (DMSO: DPBS volume ratio =2:8) to a concentration 
of 20 mg/ml, and the mixture was incubated in water bath at 70 °C with  sonication for 12 
h. The products were purified against extensive dialysis using a cellulose membrane 
(MWCO 7 kDa, Union Carbide, NY). The final products were lyophilized and stored at 
-20 °C for future use. The molecular weight of the polymers was determined by gel 
permeation chromatography (GPC). 
Synthesis of RGD-g- dPOA 
(CR9KC)n was dissolved in DPBS at a concentration of 10 mg/ml and reacted with 
N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP) of 0.2 molar equivalents of 
CR9KC monomers in DPBS at room temperature for 2 h, followed by a reaction with 
excess Ac-CGRGDS-NH2 peptides at room temperature for 24 h. The obtained 
RGD-g-dPOA was purified against extensive dialysis using a cellulose membrane 
(MWCO 7 kDa, Union Carbide, NY) and lyophilized and stored at -20 °C for future use. 




siRNA in DPBS (2 μM) was added to an equal volume of solutions of cationic 
materials (such as the arginine peptides and tadpole dendrimers) at indicated 
concentrations to achieve varied N/P ratios, and the samples were incubated at room 
temperature for 20 min. Gel electrophoresis was performed to visualize the unloaded 
siRNA in solutions. Samples were detected in a 3.5% agarose gel in pH 8.5 TBE buffer, 
and images were captured by a Tanon-1600 Gel Documentation System (Tanon, Shanghai, 
China). 
Fluorescent dye exclusive assay 
100 × Gene Finder was mixed with a 0.2 μM siRNA solution at a volume ratio of 
1:50, followed by incubation at room temperature for 5 min. The Gene Finder-combined 
siRNA was mixed with cationic materials as described above. The fluorescent signals of 
the samples were determined by a SpectraMax M2 microplate reader (MD, USA) to detect 
unloaded siRNA in solutions (Ex: 488nm, Em: 522nm). 
RNase protection assay and GSH treatment 
siRNA-loaded arginine peptide particles were treated with 5 unit RNase at 37 °C 
for 30 min, and the treatment was terminated by a 1% SDS solution. Samples were treated 
with excess polyacrylic acid (PAA) to release siRNA from particles, followed by 
electrophoresis in a 3.5% agarose gel in 0.5 × TBE buffer (0.045mol/L Tris, 0.045mol/L 
boric acid, 0.001mol/L EDTA). Images were captured by a Tanon-1600 Gel 
Documentation System (Tanon, Shanghai, China). 
For the GSH treatment assay, siRNA-loaded arginine peptide particles were treated 




excess PAA at room temperature for 30 min, and then samples were analyzed by 
electrophoresis in a 3.5% agarose gel. 
Particle size and zeta-potential analysis 
To characterize the particle size and zeta-potential of the siRNA-loaded particles, 
samples were prepared as described in their corresponding sections and diluted 10 times by 
deionized water, followed by analysis through light scattering experiments with a 
ZetaPALS machine (Brookhaven Instruments, NY). 
Establishment of the luciferase stably expressing cell line 
Luciferase expressing plasmid pGL4.51 was transfected into A549 cells with 
Lipofectamine 2000 according to the manufacturer’s protocol, followed by 800 μg/ml 
G418’s selection for two weeks. Survival clones were transferred into a 96-well plate and 
selected by 400 μg/ml G418 for another 2 months. The luciferase expression was measured 
by a Bright-Glo luciferase assay system (Promega). The obtained stable transfectants were 
termed as A549-luci and cultured in F12 nutrient medium with 10% FBS and 1% 
streptomycin and penicillin. 
MTS assay 
MTS assay was performed according to the manufacturer’s protocol. In brief, cells 
were seeded into a 96-well plate at a confluency around 80%. Tested materials or delivery 
particles were added to cells at indicated concentrations and incubated with cells for 6- 48 h 
according to the transfection experiments. The cell culture supernatants were replaced by 
100 μl of fresh medium and 20 μl of MTS reagent. After incubation at 37 °C with 5% CO2 






A549-luci cells (or HepG2 cells) were seeded into a 96-well plate at a density of 
1.2×10
4
 cells/well one day before transfection. siRNA-loaded dPOA particles or 
RGD-g-dPOA particles were added to cells in serum-free F12 (or DMEM) medium at a 
siRNA concentration of 100 nM, and after 6 h incubation the medium was replaced by 
fresh culture medium. Luciferase expression and total protein amount were determined by 
a Bright-Glo luciferase assay system and BCA protein assay 48 h after transfection. 
Fluorescence microscopy and flow cytometry analysis 
The procedure of cy3-siRNA transfection was the same as the non-labeled siRNA 
described in their corresponding sections. After transfection, cells were washed twice with 
DPBS, and nuclei were stained with DAPI for 10 min. Images were captured by an IX71 
fluorescence microscopy (Olympus, Japan), and cellular uptake rates of materials were 
compared. For flow cytometry analysis, cy3-siRNA transfected cells were washed by 
DPBS twice and detached from the plate bottom after trypsin treatment. Flow cytometry 
was conducted by FASCalibur (Becton, Dickinson and Company, NJ), and data were 
processed using Summit 4.0 software. 
Synthesis of PAMAM-hydrazide (PAMAM-HYD) and saccharide-modified 
PAMAM-HYDs 
PAMAM-HYD and saccharide-modified PAMAM-HYD dendrimers were 
synthesized following a published method in our lab [40]. 50 mg/ml G4.0 PAMAM 




at 37 °C for 48 h, followed by rotary evaporation to remove the unreacted methyl acrylate 
at 65 °C. The obtained G4.5 PAMAM was further reacted with hydrazine hydrate of 10 
molar equivalents of the methyl esters for 24 h at 55 °C under reflux, followed by rotary 
evaporation and extensive dialysis. The synthesis of PAMAM-HYD was conducted by 
Xiaopeng Liu, who was a graduate student in our lab. 
To conjugate saccharide ligands, 10 mg/ml PAMAM-HYD was reacted with 
saccharide molecules of 10 molar equivalents of hydrazide groups in pH 5.0 phosphate 
buffer for 24 h at 50 °C. The crude saccharide-modified dendrimers were purified via 
dialysis. 
1
H-NMR was used to determine the saccharide modification level in each 
product. The tested saccharides included mannose, glucose, GlcNAc, galactose, and 
lactose, termed as Man-, Glu-, GlcNAc-, Gal-, and Lac-PAMAM. The synthesis of these 
glycodendrimers was conducted by Xiaopeng Liu [40]. 
To synthesize GalNAc-PAMAM-HYDs with different GalNAc modification 
levels, PAMAM-HYD was reacted with GalNAc of 0.5, 1 or 1.5 molar equivalents of the 
hydrazide groups according to the same protocol described above. The GalNAc 
modification level was analyzed by 
1
H-NMR.  
Screening of the efficient ligand for HepG2 cells 
To identify the potent saccharide ligand for HepG2 cells, different 
saccharide-modified PAMAM-HYDs were labeled with fluorescein and incubated with 
HepG2 cells at a concentration of 1.6 μM for 24 h. The cells were washed with DPBS, 
detached from the culture plate, and subjected to flow cytometry analysis by a 




Preparation of crosslinked delivery systems 
To study the complexation between siRNA and neutral dendrimers, 2 μM siRNA 
was added to an equal volume of dendrimer solutions of indicated concentrations at 
pH5.0 and 7.4, respectively. 
To prepare crosslinked systems, 2 μM siRNA and 25 mM glutaraldehyde were 
first mixed at pH 5.0 for 5 min, and then the dendrimer solution was added to the mixture, 
allowing the incubation at 37 °C for 1 h. To terminate the crosslinking reaction, excessive 
adipic acid dihydrazide (ADH) molecules were added to block the unreacted 
glutaraldehyde, and meanwhile the solution pH was adjusted to 7 using a NaOH solution. 
To purify the siRNA-loaded crosslinked particles, the samples were subjected to dialysis 
in PBS at pH 7.4 [185].  
Gel retardation analysis and fluorescent dye exclusive assay 
To determine whether siRNA interacted with the neutral dendrimers or was 
loaded in the crosslinked particles, gel electrophoresis was performed to visualize the 
unloaded siRNA in solution. Samples were detected in a 3.5% agarose gel in pH 8.5 TBE 
buffer, and images were captured by a Tanon-1600 Gel Documentation System (Tanon, 
Shanghai, China). 
Unloaded siRNA was also quantitatively analyzed by nucleic acid fluorescent dye. 
Briefly, siRNA-dendrimer complexes or siRNA-loaded crosslinked particles were 
prepared as described above, and Gene Finder was added to the obtained solutions. After 
5 min incubation, the fluorescent signal was measured and recorded by a SpectraMax M2 





First, luciferase-expressing HepG2 cells were produced by the transfection of 
pGL4.51 plasmid (Promega) with Lipofectamine 2000. 24 h after the plasmid 
transfection, 10 pmol siRNA against the firefly luciferase gene was loaded in crosslinked 
particles as described above, and the particles were added to HepG2 cells in DMEM 
medium containing 10% FBS, allowing a siRNA concentration of 50 nm during 
transfection. The luciferase protein expression was measured by a Bright-Glo luciferase 
assay system after 48 h, and the total protein was measured via a BCA protein assay kit. 
Fluorescence microscopy analysis 
To visualize the cell uptake, neutral dendrimers were labeled with 
NHS-fluorescein molecules and incubated with HepG2 cells for 24 h before imaged. 
Meanwhile, cy3-siRNA loaded crosslinked particles were prepared as described above 
and incubated with HepG2 cells for 12 h. Cells were washed with DPBS thrice before 
fluorescence images were captured by an IX71 fluorescence microscope (Olympus, 
Japan). 
Synthesis of tadpole dendrimeric materials 
The synthesis of the tadpole dendrimeric materials was divided into three steps. 
First, 10 mg/ml cystamine core G4.0 PAMAM (Sigma) was reacted with dithiothreitol 
(DTT, Sigma) of 10 molar equivalents of disulfide bonds for 24 h in PBS, followed by 
ultrafiltration via 3 KDa MWCO Amicon® Ultra Centrifugal Filters (Millipore). Second, 
the reduced PAMAM with exposed thiol groups was reacted with Py-PEG-Py (Jiaxing 




were purified by extensive dialysis. Third, Ac-CRRRRRRRRR-NH2 (R9), 
Ac-CGGWRKKRRQRRR-NH2 (TAT) (GL Biochem Ltd), or cysteine (Sigma) of 1.5 
molar equivalents of PEG was reacted, respectively, with the intermediates for 24 h, 
followed by dialysis using a 7 kDa MWCO cellulose membrane. The structure of tadpole 




Particle size and zeta-potential 
Particle sizes were analyzed by a 90Plus Particle Size Analyzer instrument, and 
the zeta-potentials were measured by a Zeta Sizer Nano ZS90 instrument. 
siAT1R transfection in CMs 
CMs were isolated from Sprague–Dawley (SD) rat pups (Charles River Labs) as 
described in literature [99], and cells were allow to grow to 80% confluency before 
further experiments. Tadpole dendrimers loaded with or without siRNA against AT1R 
(5’-UGAAGAGCCUGAUCAAAUAdTdT-3’ (sense) and 3’-dTdT 
ACUUCUCGGACUAGUUUAU-5’ (antisense), Dharmacon) were prepared as described 
above in DMEM, and the siRNA-loaded particles were incubated with CMs in DMEM 
medium containing 2% serum for 24 h before RNA isolation [96].  
qPCR to detect gene expression level 
Total RNA was isolated using Trizol reagent according to the manufacturer’s 
protocol, followed by reverse transcription by an M-MLV kit (Invitrogen) to produce 
cDNA. cDNA was subjected to quantitative real-time PCR (qPCR) by Power SYBR 




the primers below. Gene expression levels were normalized relative to that of the 
housekeeping gene 18S, and the results were presented as fold changes for siRNA-loaded 
particles relative to the empty dendrimer vehicles for the in vitro transfection [96]. 
 
Table A.1 Primer sequences used in qPCR 
Gene 
name 
















To get the IR injury model, adult SD rats were anesthetized with 1-3% isoflurane 
followed by heart exposure, and the left descending coronary artery was occluded for 30 
min before releasing the suture. Operated animals were randomly divided into 3 groups, 
and immediately after blood flow recovery, 80 μl samples were injected 
intramyocardially at 3 regions of the border zone: saline (IR group), saline containing 
empty dendrimer (IR + dendrimer group), or saline containing siRNA- loaded particles 




went through chest opening without artery ligation were kept as sham animals. After 
injection, chests were closed and rats were allowed to recover on a heating pad. All 
animal studies were approved by Emory University Institutional Animal Care and Use 
Committee [96]. 
At the 3-day time point, cardiac functions of the animals were measured by 
echocardiography and Pressure-Volume (PV) cardiac hemodynamics, and then animals 
were subjected to scarification. Total RNA was isolated from the left ventricle tissue 
using Trizol reagent, and the copy number of genes was determined by qPCR using a 
standard curve method and normalized to 18S [96]. 
Infarct size measurement 
Three days after injection, rats were anesthetized with inhaled isoflurane, and the 
coronary artery was re-occluded at the same place of occlusion as the initial surgery. 10% 
filtered Evan’s blue dye was used to perfuse the heart through the aorta until the blue dye 
fulfilled the tissue beyond the infarct area. Hearts were sliced and soaked in a 1% 
2,3,5-triphenyltetrazolium chloride (TTC) solution for 15-20 min. Finally, the heart slides 
were fixed in 4% paraformaldehyde over night before imaged. ImageJ was used to trace 
the areas of three different colors: the blue stands for the viable tissue, the red stands for 
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